ChIP-Atlas / in silico ChIP for GWAS

GWAS trait	Num of LD-DHS	Min(Log P)
1,5-anhydroglucitol levels	1	-2.5
3-hydroxy-1-methylpropylmercapturic acid levels in smokers	576	-3.9
3-hydroxypropylmercapturic acid levels in smokers	744	-4.5
3-month functional outcome in ischaemic stroke (modified Rankin score)	140	-3.3
3-month functional outcome in lacunar ischaemic stroke (modified Rankin score)	10	-1.8
3-month functional outcome in non-lacunar ischaemic stroke (modified Rankin score)	27	-3.9
6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)	238	-3.4
Abdominal aortic aneurysm	24	-5.2
Ability to confide in someone	39	-2.6
Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis)	3	-5.2
Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction)	33	-2.9
Accelerometer-based physical activity measurement (average acceleration)	23	-4.2
	1	-2.4
Achilles tendinopathy	5	-3.5
Acne (severe)	124	-7.0
Acoustic startle blink response	43	-3.1
ACPA-positive rheumatoid arthritis (smoking interaction)	5	-3.2
Activated partial thromboplastin time	49	-2.9
Acute anterior uveitis (with or without ankylosing spondylitis)	12	-4.8
Acute graft versus host disease in bone marrow transplantation (donor effect)	72	-4.0
Acute graft versus host disease in bone marrow transplantation (recipient effect)	59	-4.9
Acute insulin response	66	-5.1
Acute kidney injury in coronary artery bypass surgery (creatinine rise)	5	-2.9
Acute kidney injury in critical illness	6	-3.2
Acute lymphoblastic leukemia (adolescents and young adults)	2	-2.8
Acute lymphoblastic leukemia (B-cell precursor)	48	-7.2
Acute lymphoblastic leukemia (childhood)	223	-4.7
Acute lymphoblastic leukemia in childhood (B cell precursor)	44	-5.3
Acute-on-chronic liver failure in hepatitis B	1	-2.8
Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	51	-2.3
ADAMTS13 activity	1	-2.4
Addiction	12	-5.9
Adenocarcinoma	17	-8.5
Adiponectin levels	276	-3.9
Adiponectin levels (BMI-adjusted)	14	-3.2
Adiponectin levels in pregnancy	5	-2.5
Adiposity	46	-6.3
Adolescent idiopathic scoliosis	6967	-10.1
Adolescent idiopathic scoliosis (severe)	1	0.0
Adult asthma	65	-3.1
Advanced age-related macular degeneration	131	-4.9
Advanced glycation end-product levels	16	-4.9
Adventurousness	988	-4.6
Adverse response to antithyroid drugs in Graves disease	2	-2.2
Adverse response to aromatase inhibitors	6	-4.2
Adverse response to chemotherapy in breast cancer (alopecia)	2	-1.1
Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)	54	-4.1
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)	13	-2.8
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)	5	-2.4
Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)	42	-4.3
Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)	41	-4.3
Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)	26	-2.6
Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)	40	-4.4
Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)	6	-4.4
Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	84	-3.8
Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)	30	-6.4
Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)	18	-2.4
Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)	13	-4.3
Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)	21	-9.4
Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)	86	-3.5
Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)	9	-4.1
Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)	20	-4.6
Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)	21	-6.2
Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)	9	-2.9
Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)	29	-2.9
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)	14	-4.1
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)	31	-3.9
Adverse response to lamotrigine and phenytoin	97	-3.7
Adverse response to radiation therapy	31	-4.3
Affective disorder and suicide attempts	81	-4.0
Age at first birth	22	-3.0
Age at first sexual intercourse	89	-3.2
Age at loss of ambulation in Duchenne muscular dystrophy	113	-2.8
Age at menopause	176	-5.0
Age at smoking initiation in chronic obstructive pulmonary disease	55	-2.8
Age at voice drop	57	-4.7
Age of smoking initiation	138	-2.8
Age of smoking initiation (MTAG)	1014	-8.3
Age-related cataracts	6	-2.6
Age-related disease endophenotypes	92	-5.1
Age-related diseases and mortality	78	-2.7
Age-related diseases, mortality and associated endophenotypes	166	-3.7
Age-related hearing impairment	164	-3.8
Age-related macular degeneration	162	-5.9
Age-related macular degeneration (choroidal neovascularisation)	1	-1.9
Age-related macular degeneration (geographic atrophy)	3	-2.9
Age-related macular degeneration (smoking status interaction)	10	-1.6
Age-related nuclear cataracts	86	-3.3
Age spots	10	-3.3
Aggressiveness in attention deficit hyperactivity disorder	128	-3.3
Aggressive periodontitis	1	0.0
Aggressive periodontitis (sex interaction)	18	-3.9
Aging	55	-4.1
Aging (facial)	1	-1.6
Aging (time to death)	15	-2.4
Aging (time to event)	63	-4.2
Aging traits	77	-3.4
AIDS	20	-2.4
AIDS progression	13	-4.4
Airflow obstruction	106	-3.1
Airway imaging phenotypes	97	-3.1
Airway responsiveness in chronic obstructive pulmonary disease	55	-5.5
Airway wall thickness	41	-3.2
Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)	147	-2.6
Alanine aminotransferase levels	32	-2.6
Alanine aminotransferase levels in excessive alcohol consumption	59	-5.7
Alanine aminotransferase levels in low alcohol consumption	107	-3.7
Alanine transaminase levels	79	-4.7
Albumin-globulin ratio	93	-4.6
Alcohol and nicotine co-dependence	23	-4.4
Alcohol consumption	246	-3.0
Alcohol consumption (drinkers vs non-drinkers)	1	-1.9
Alcohol consumption (drinks per week)	679	-4.4
Alcohol consumption (drinks per week) (MTAG)	855	-4.8
Alcohol consumption in current drinkers	3	-1.7
Alcohol consumption (max-drinks)	33	-5.5
Alcohol consumption over the past year	7	-1.9
Alcohol consumption (transferrin glycosylation)	1	-3.3
Alcohol dependence	224	-7.8
Alcohol dependence (age at onset)	169	-3.6
Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis	5	-1.9
Alcohol dependence symptom count	129	-3.4
Alcoholic chronic pancreatitis	184	-10.2
Alcoholism (12-month weekly alcohol consumption)	38	-5.3
Alcoholism (alcohol dependence factor score)	15	-5.5
Alcoholism (alcohol use disorder factor score)	5	-2.5
Alcoholism (heaviness of drinking)	38	-3.3
Alcohol misuse (trauma interaction)	7	-3.8
Alcohol use disorder (consumption score)	145	-7.2
Alcohol use disorder (dependence and problematic use scores)	1	0.0
Alcohol use disorder (total score)	36	-7.1
Allergic dermatitis (nickel)	11	-3.1
Allergic disease (asthma, hay fever or eczema)	609	-15.9
Allergic rhinitis	262	-4.4
Allergic rhinitis in asthma	3	-3.0
Allergic rhinitis in non-asthmatics	40	-2.9
Allergic sensitization	101	-7.3
Allergy	63	-4.6
Alloimmunization response to pregnancy (HLA class I)	1	-2.6
Alloimmunization response to red blood cell transfusion in sickle cell anemia	2	-4.1
Alopecia areata	143	-7.1
Alzheimer disease and age of onset	591	-2.9
Alzheimer's disease	227	-6.8
Alzheimer's disease (age of onset)	39	-3.4
Alzheimer's disease (APOE e4 interaction)	8	-3.2
Alzheimer's disease biomarkers	34	-4.1
Alzheimer's disease (cognitive decline)	72	-3.4
Alzheimer's disease in APOE e4+ carriers	48	-2.4
Alzheimer's disease in APOE e4- carriers	103	-5.3
Alzheimer's disease (late onset)	373	-6.3
Alzheimer's disease or family history of Alzheimer's disease	382	-13.8
Alzheimer's disease progression score	39	-2.6
Alzheimer's disease (survival time)	19	-4.8
Alzheimer's disease with language domain impairment	30	-3.7
Alzheimer's disease with memory domain impairment	3	-3.0
Alzheimer's disease with multiple cognitive domain impairments	11	-4.6
Alzheimer's disease with no specific cognitive domain impairment	15	-4.8
Alzheimer's disease with visuospatial domain impairment	123	-5.2
Amino acid levels	29	-3.5
Amyotrophic lateral sclerosis	302	-6.9
Amyotrophic lateral sclerosis (age of onset)	48	-4.1
Amyotrophic lateral sclerosis (C9orf72 mutation interaction)	8	-4.4
Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals	20	-4.1
Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals	37	-2.1
Amyotrophic lateral sclerosis (sporadic)	498	-5.3
Androgen levels	4	-2.0
Anger	65	-4.4
Angiotensin-converting enzyme activity	4	-3.1
Angiotensin-converting enzyme inhibitor intolerance	86	-5.4
Ankle-brachial index	3	-2.3
Ankle injury	166	-7.6
Ankylosing spondylitis	227	-7.0
Anorexia nervosa	126	-4.6
Anorexia nervosa (excluding migration to or from binge-eating disorder or bulimia nervosa)	11	-3.2
Anorexia nervosa or obsessive-compulsive disorder	32	-6.5
Anterior cruciate ligament rupture	37	-3.5
Anthropometric traits	78	-3.3
Anthropometric traits (multi-trait analysis)	56	-2.7
Antibody level in response to infection	44	-2.3
Antibody status in Tripanosoma cruzi seropositivity	46	-3.6
Anticoagulant levels	36	-3.3
	10	-3.0
Antidepressant treatment resistance (number of drugs prescribed)	25	-3.1
Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG levels	1	0.0
Anti-Mullerian hormone levels in pre-menopausal women of late reproductive age	21	-3.5
Antineutrophil cytoplasmic antibody-associated vasculitis	47	-3.5
antipsychotic drug dosage in schizophrenia or schizoaffective disorder	98	-4.6
Antipsychotic drug-induced QTc interval change in schizophrenia	76	-2.0
Antipsychotic drug-induced QTc interval prolongation	32	-5.2
Antipsychotic drug-induced weight gain	1	0.0
Anti-saccade error rate in psychotic disorders	2	-2.7
Anti-saccade response	261	-4.9
Anti-thyroid drug induced agranulocytosis	2	-4.3
Antitragus size	3	-3.0
Anxiety and major depressive disorder	31	-6.5
Anxiety disorder	44	-4.6
Anxiety in major depressive disorder	29	-2.8
Anxiety/tension (special factor of neuroticism)	75	-3.9
Aortic root size	85	-4.5
Aortic stiffness	21	-2.6
Aortic valve stenosis	33	-4.1
Apolipoprotein A1 levels	12	-6.2
Appendicitis	7	-2.6
Appendicular lean mass	41	-2.9
Area under the curve of insulin levels	2	-5.4
Arterial stiffness	8	-2.6
Arthritis (juvenile idiopathic)	45	-4.0
Asparaginase hypersensitivity in acute lymphoblastic leukemia	6	-3.9
Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)	1	-2.3
Aspartate aminotransferase levels	105	-5.4
Aspartate aminotransferase levels in excessive alcohol consumption	46	-2.9
Aspartate aminotransferase levels in low alcohol consumption	73	-3.3
Asperger disorder	43	-3.0
Asthma	1128	-11.8
Asthma and hay fever	139	-5.3
Asthma (bronchodilator response)	11	-3.2
Asthma (childhood onset)	704	-11.2
Asthma-chronic obstructive pulmonary disease overlap syndrome	10	-1.7
Asthma (corticosteroid response)	16	-3.0
Asthma exacerbations in inhaled corticosteroid treatment	52	-4.5
Asthma (moderate or severe)	134	-6.0
Asthma or allergic disease (pleiotropy)	155	-5.4
Asthma or chronic obstructive pulmonary disease	13	-4.7
Asthma (sex interaction)	9	-2.8
Asthma (toluene diisocyanate-induced)	32	-2.9
Asymmetrical dimethylarginine levels	40	-2.8
Atazanavir levels	6	-4.6
Atopic dermatitis	200	-8.7
Atopic march	81	-6.9
Atopy	16	-4.1
Atrial fibrillation	1042	-5.2
Atrial fibrillation/atrial flutter	37	-3.3
Atrioventricular conduction	15	-2.8
Atrioventricular septal defects in Down syndrome	1	-2.7
Attention deficit hyperactivity disorder	605	-4.9
Attention deficit hyperactivity disorder and conduct disorder	105	-4.4
Attention deficit hyperactivity disorder (combined symptoms)	30	-3.6
Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)	57	-3.5
Attention deficit hyperactivity disorder (inattention symptoms)	45	-3.3
Attention deficit hyperactivity disorder motor coordination	2	-1.3
Attention deficit hyperactivity disorder or amygdala volume (pleiotropy)	7	-2.1
Attention deficit hyperactivity disorder or cannabis use	179	-4.8
Attention deficit hyperactivity disorder or caudate nucleus volume (pleiotropy)	1	-3.6
Attention deficit hyperactivity disorder or intracranial volume (pleiotropy)	8	-1.9
Attention deficit hyperactivity disorder symptom score	23	-3.1
Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction)	28	-2.5
Attention deficit hyperactivity disorder (time to onset)	34	-4.2
Attention function in attention deficit hyperactive disorder	187	-4.2
Autism	24	-4.0
Autism and educational attainment (MTAG)	14	-5.2
Autism and major depressive disorder (MTAG)	11	-3.9
Autism spectrum disorder	162	-5.3
Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	454	-3.9
Autism spectrum disorder or schizophrenia	556	-6.3
Autism spectrum disorder-related traits	20	-3.7
Autoimmune hepatitis type-1	7	-5.1
Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis)	23	-2.5
Autoimmune traits	314	-7.4
Automobile speeding propensity	204	-4.9
Axial length	61	-4.7
Axial length or spherical error (univariate decomposition analysis)	23	-4.2
B6 vitamer levels (multivariate analysis)	7	-5.0
Bacteremia	42	-4.1
Bacterial meningitis	111	-2.7
Balding	5	-2.7
Balding type 1	2068	-11.1
Barrett's esophagus	33	-3.3
Barrett's esophagus or Esophageal adenocarcinoma	29	-5.7
Barrett's esophagus x pack-years of smoking exposure interaction	11	-4.9
Basal cell carcinoma	87	-4.3
Basal ganglia growth	4	-1.7
Basal metabolic rate	11	-3.0
Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma	1	0.0
Basophil percentage of granulocytes	126	-15.6
Basophil percentage of white cells	148	-9.5
B cell acute lymphoblastic leukaemia (abnormal cytogenetics)	2	-2.8
B cell acute lymphoblastic leukaemia (hyperdiploid negative)	2	-2.8
B cell acute lymphoblastic leukaemia in adulthood	2	-2.8
B cell acute lymphoblastic leukaemia in young adulthood	2	-2.8
B cell acute lymphoblastic leukaemia (normal cytogenetics)	2	-2.8
B cell acute lymphoblastic leukaemia (Philadelphia chromosome negative)	2	-2.8
B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)	16	-3.8
B cell non-Hodgkin lymphoma	10	-4.1
Beard thickness	53	-3.9
Behavioral disturbance or psychiatric symptoms and prion disease	18	-3.1
Behavioral disturbance or psychiatric symptoms in prion disease	8	-4.3
Behavioural changes in frontotemporal lobe dementia	6	-2.7
Behavioural disinhibition (generation interaction)	84	-2.7
Behcet's disease	38	-5.2
Benign prostatic hyperplasia and lower urinary tract symptoms	119	-5.2
Benign prostatic hyperplasia and lower urinary tract symptoms (prostate cancer excluded)	112	-5.3
Benign prostatic hyperplasia and/or lower urinary tract symptoms	3	-2.0
β2-Glycoprotein I (β2-GPI) plasma levels	35	-2.9
beta-nerve growth factor levels	57	-3.0
Beta thalassemia/hemoglobin E disease	18	-5.1
Biliary atresia	32	-4.7
Bilirubin levels	90	-3.7
Binge eating behaviour and bipolar disorder	45	-2.2
Binge eating behaviour in bipolar disorder	5	-2.2
Biochemical measures	157	-3.3
Biomedical quantitative traits	92	-6.3
Bipolar disorder	1218	-4.2
Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder	7	-4.6
Bipolar disorder (age of onset and psychotic symptoms)	2	-2.3
Bipolar disorder and eating disorder	14	-4.3
Bipolar disorder and schizophrenia	703	-5.0
Bipolar disorder (body mass index interaction)	283	-7.0
Bipolar disorder (early onset)	5	-3.5
Bipolar disorder (inflammation and infection response interaction)	31	-3.4
Bipolar disorder lithium response (categorical) or schizophrenia	22	-3.4
Bipolar disorder lithium response (continuous) or schizophrenia	2	-2.4
Bipolar disorder or attention deficit hyperactivity disorder	41	-6.2
Bipolar disorder or major depressive disorder	103	-3.9
Bipolar disorder with mood-incongruent psychosis	69	-3.8
Bipolar I disorder	249	-4.7
Birth weight	828	-5.8
Bitter taste perception	1	-2.2
Bitter taste perception (multivariate analysis)	5	-5.3
Black vs. blond hair color	1	0.0
Black vs. red hair color	1	0.0
Bladder cancer	117	-34.5
Bladder cancer (smoking interaction)	18	-3.7
Blond vs. brown/black hair color	886	-9.4
Blond vs. brown hair color	54	-6.1
Blond vs non-blond hair color	60	-6.0
Blood and toenail selenium levels	7	-2.9
Blood metabolite levels	183	-10.2
Blood metabolite ratios	59	-3.9
Blood osmolality (transformed sodium)	121	-4.1
Blood pressure	503	-3.0
Blood pressure (age interaction)	8	-2.8
Blood pressure (anthropometric measures interaction)	24	-3.5
Blood pressure measurement (cold pressor test)	11	-3.0
Blood pressure measurement (high sodium and potassium intervention)	55	-3.5
Blood pressure measurement (high sodium intervention)	26	-3.3
Blood pressure measurement (low sodium intervention)	33	-4.1
Blood pressure (smoking interaction)	133	-3.4
Blood pressure traits (multi-trait analysis)	39	-3.8
Blood protein levels	3220	-13.6
Blood sugar levels	75	-4.9
Blood trace element (Cu levels)	21	-2.5
Blood trace element (Se levels)	48	-5.3
Blood trace element (Zn levels)	37	-2.6
Blood urea nitrogen levels	681	-9.1
BMI (adjusted for smoking behaviour)	422	-5.3
BMI in non-smokers	297	-3.4
BMI in smokers	183	-5.9
BMI (smoking interaction)	61	-8.8
Body fat distribution (arm fat ratio)	165	-4.7
Body fat distribution (leg fat ratio)	230	-4.2
Body fat distribution (trunk fat ratio)	215	-4.3
Body fat mass	180	-4.6
Body fat percentage	459	-3.8
Body mass in chronic obstructive pulmonary disease	30	-7.9
Body mass index	7863	-9.0
Body mass index (adult)	179	-3.5
Body mass index (age <50)	119	-8.0
	132	-4.1
Body mass index (age interaction)	38	-5.9
Body mass index (alcohol intake interaction)	6	-3.7
Body mass index and cholesterol (psychopharmacological treatment)	25	-3.2
Body mass index and waist-hip ratio (pleiotropy)	34	-6.1
Body mass index (change over time)	35	-2.9
Body mass index (change over time) in cancer or chronic obstructive pulmonary disease	19	-4.3
Body mass index (change over time) in chronic obstructive pulmonary disease	29	-4.4
Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease	8	-4.1
Body mass index (change over time) in lung cancer	12	-2.6
Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease	12	-3.6
Body mass index (dietary energy interaction)	4	-1.7
Body mass index (education interaction)	53	-3.3
Body mass index (ever vs never smoking interaction)	17	-2.2
Body mass index in asthmatics	27	-5.3
Body mass index in non-asthmatics	38	-4.3
Body mass index in physically active individuals	383	-4.2
Body mass index in physically inactive individuals	231	-7.7
Body mass index (joint analysis main effects and physical activity interaction)	434	-5.8
Body mass index (joint analysis main effects and smoking interaction)	483	-6.1
Body mass index (physical activity interaction)	10	-3.1
Body mass index (recreational physical activity interaction)	24	-7.7
Body mass index (smoking years interaction)	43	-2.4
Body mass index (SNP x SNP interaction)	72	-5.0
Body mass index x age interaction	60	-4.2
Body mass index x sex x age interaction (4df test)	159	-7.3
Bone erosion in rheumatoid arthritis	1	-4.4
Bone fracture in osteoporosis	23	-3.7
Bone mineral accretion in asthma (oral corticosteroid dose interaction)	30	-1.9
Bone mineral density	237	-3.9
Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia	4	-2.0
Bone mineral density (femoral neck)	3	-4.4
Bone mineral density (femoral neck) in inflammatory bowel disease	11	-5.0
Bone mineral density (hip)	273	-4.3
Bone mineral density (hip) and age at menarche	36	-5.3
Bone mineral density (lumbar spine) in inflammatory bowel disease	36	-11.0
Bone mineral density (paediatric, lower limb)	1	-2.8
Bone mineral density (paediatric, skull)	32	-3.8
Bone mineral density (paediatric, total body less head)	66	-3.8
Bone mineral density (paediatric, upper limb)	82	-4.3
Bone mineral density (spine)	122	-5.0
Bone mineral density (spine) and age at menarche	20	-5.8
Bone mineral density (total hip)	123	-4.7
Bone mineral density (Ward's triangle area)	88	-2.7
Bone mineral density (wrist)	29	-2.8
Bone mineral density x blood lead interaction in current smokers (1df test)	1	-2.4
Bone mineral density x blood lead interaction in current smokers (2df test)	4	-4.3
Bone properties (heel)	67	-3.7
Bone ultrasound measurement (broadband ultrasound attenuation)	76	-5.7
Bone ultrasound measurement (velocity of sound)	61	-3.8
Borderline personality disorder	34	-3.5
Bortezomib-induced peripheral neuropathy in multiple myeloma	23	-1.9
Brain connectivity	69	-3.2
Brain cytoarchitecture	10	-2.6
Brain glucose metabolism (fluorodeoxyglucose uptake)	15	-3.4
Brain imaging	40	-6.9
Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction)	64	-3.7
Brain imaging measurements	3	-3.0
Brain lesion load	14	-3.4
Brain structure	67	-2.6
Brain structure (hippocampal volume)	21	-3.9
Brain structure (temporal lobe volume)	42	-3.1
Brain volume in infants (cerebrospinal fluid)	14	-3.2
Brain volume in infants (grey matter)	49	-3.3
Brain volume in infants (intracranial brain volume)	3	-3.1
Brain volume in infants (white matter)	7	-2.2
Branched-chain amino acid levels (Isoleucine)	30	-4.9
BRCA1/2-negative high-risk breast cancer	52	-2.9
Breast cancer	2692	-16.7
Breast cancer and/or colorectal cancer	16	-5.0
Breast cancer (early onset)	47	-4.6
Breast cancer (estrogen-receptor negative)	250	-9.4
Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)	17	-7.7
Breast cancer (estrogen-receptor positive)	21	-4.4
Breast cancer-free interval (treatment with aromatase inhibitor)	4	-4.1
Breast Cancer in BRCA1 mutation carriers	47	-7.2
Breast cancer in BRCA2 mutation carriers	5	-2.8
Breast cancer in childhood cancer survivors	6	-2.5
Breast cancer in childhood cancer survivors treated with less than 10 gray radiotherapy	30	-4.1
Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy	4	-2.7
Breast cancer (male)	56	-16.7
Breast cancer (menopausal hormone therapy interaction)	5	-3.3
Breast cancer (progesterone-receptor positive)	7	-6.4
Breast cancer (prognosis)	18	-5.4
Breast cancer specific mortality in breast cancer	49	-2.9
Breast cancer specific mortality in estrogen receptor negative breast cancer	53	-4.7
Breast cancer specific mortality in estrogen receptor positive breast cancer	62	-4.7
Breast cancer (survival)	19	-4.0
Breastfeeding duration	10	-2.9
Breast milk fatty acid composition (infant genotype effect)	32	-2.5
Breast milk fatty acid composition (maternal genotype effect)	35	-2.3
Breast size	232	-5.6
Broad depression or bipolar disorder	1	-3.1
Broad depression or major depressive disorder (self-reported)	25	-2.1
Broad depression or schizophrenia	65	-2.9
Bronchial neuroendocrine tumor	1	0.0
Bronchodilator response in asthma	5	-2.6
Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)	4	-2.3
Bronchopulmonary dysplasia	69	-2.9
Bronchopulmonary dysplasia in preterm infants	44	-3.4
Brooding (response to stress)	13	-4.2
Brown vs. black hair color	168	-6.5
Brown vs. non-brown hair color	60	-6.0
Bulimia nervosa	129	-3.8
Caffeine consumption	25	-3.3
Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level)	16	-4.2
Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level)	3	-3.1
Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) level)	1	-1.8
Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio)	32	-4.9
Calcific aortic valve stenosis	15	-5.5
Calcium levels	253	-4.2
Callous-unemotional behaviour	11	-2.8
Cancer	37	-2.8
Cancer (pleiotropy)	68	-3.4
Cannabis dependence	113	-2.9
Cannabis dependence symptom count	175	-3.8
Cannabis use	49	-3.4
Cannabis use (age at onset)	43	-1.5
Cannabis use (initiation)	103	-4.7
Capecitabine sensitivity	68	-3.6
Carboplatin disposition in epthelial ovarian cancer	157	-2.5
Cardiac hypertrophy	129	-3.3
Cardiac muscle measurement	70	-5.0
Cardiac repolarization	25	-5.2
Cardiac structure and function	26	-3.3
Cardiac Troponin-T levels	168	-3.4
Cardiometabolic and hematological traits	72	-2.4
Cardiovascular disease	1326	-4.3
Cardiovascular disease in hypertension (calcium channel blocker interaction)	6	-4.8
Cardiovascular disease risk factors	22	-4.8
Cardiovascular event in rheumatoid arthritis	6	-4.2
Cardiovascular heart disease in diabetics	7	-3.1
Cardiovascular risk factors	4	-2.2
Cardiovascular risk factors (age interaction)	7	-2.4
Carotenoid and tocopherol levels	12	-4.4
Carotenoid levels (alpha-carotene)	4	-2.0
Carotid artery intima media thickness (sex interaction)	68	-3.8
Carotid atherosclerosis in HIV infection	8	-4.3
Carotid intima media thickness	54	-4.5
Carotid intima media thickness in rheumatoid arthritis	3	-1.7
Carotid plaque burden	77	-4.5
Carotid plaque burden (smoking interaction)	12	-3.6
Carotid plaques in rheumatoid arthritis	17	-5.1
Carotid plaque	19	-4.2
Carpal tunnel syndrome	102	-3.5
Caudate activity during reward	184	-5.6
Caudate volume in trauma-exposed individuals	39	-4.7
Celiac disease	396	-23.8
Celiac disease or Rheumatoid arthritis	137	-7.6
Cellular adhesion molecule (red blood cell fatty acid level interaction)	3	-2.0
Cellular nuclear factor (erythroid-derived 2)-like 2 levels	25	-4.1
Central corneal thickness	294	-5.1
Cephalic index	72	-5.7
Cerebellum growth	2	-2.2
Cerebral amyloid angiopathy	20	-2.3
Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging)	122	-5.2
Cerebral amyloid deposition (PET imaging)	104	-3.2
Cerebral cortical growth	25	-6.0
Cerebrospinal AB1-42 levels in Alzheimer's disease dementia	20	-2.9
Cerebrospinal AB1-42 levels in mild cognitive impairment	3	-3.6
Cerebrospinal AB1-42 levels in normal cognition	74	-7.6
Cerebrospinal fluid AB1-42 levels	145	-5.5
Cerebrospinal fluid beta-site APP cleaving enzyme levels	68	-2.9
Cerebrospinal fluid biomarker levels	60	-3.7
Cerebrospinal fluid clusterin levels	65	-3.2
Cerebrospinal fluid clusterin levels in APOEe4+ carriers	11	-4.2
Cerebrospinal fluid p-Tau181p:AB1-42 ratio	19	-5.2
Cerebrospinal fluid p-tau levels	6	-2.2
Cerebrospinal fluid p-tau levels in Alzheimer's disease dementia	5	-4.3
Cerebrospinal fluid p-tau levels in mild cognitive impairment	9	-3.7
Cerebrospinal fluid p-tau levels in normal cognition	11	-1.8
Cerebrospinal fluid pyridoxal phosphate levels	1	-2.3
Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio	1	-2.3
Cerebrospinal fluid ?-synuclein levels	41	-4.8
Cerebrospinal fluid t-tau:AB1-42 ratio	193	-5.0
Cerebrospinal fluid t-tau levels	81	-3.4
Cerebrospinal fluid t-tau levels in Alzheimer's disease dementia	3	-3.0
Cerebrospinal fluid t-tau levels in mild cognitive impairment	4	-2.7
Cerebrospinal fluid t-tau levels in normal cognition	8	-4.0
Cerebrospinal P-tau181p levels	75	-4.0
Cerebrospinal T-tau levels	104	-4.6
Cervical artery dissection	17	-2.9
Cervical cancer	55	-3.7
Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	67	-5.9
Change in glucose in response to thiazide diuretic treatment in hypertension	19	-4.4
Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide)	3	-2.5
Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer	28	-3.8
Cheek morphology (partial least square model)	1	-4.3
Chemerin levels	50	-3.9
Chickenpox	94	-3.8
Childhood absence epilepsy	43	-3.5
Childhood and early adolescence aggressive behavior	14	-2.3
Childhood body mass index	235	-3.0
Childhood dental caries in permanent teeth	1	-3.1
Childhood ear infection	448	-10.1
Childhood onset systemic lupus erythematosus	3	-4.3
Childhood steroid-sensitive nephrotic syndrome	53	-6.4
Chin dimples	410	-4.1
Chlamydia trachomatis seropositivity	26	-8.6
Chloride levels	94	-3.7
Cholangiocarcinoma in primary sclerosing cholangitis (time to event)	10	-4.4
Cholesterol efflux capacity	5	-2.1
Cholesterol efflux capacity (ABCA-1 dependent assay)	6	-3.6
Cholesterol efflux capacity (BHK stimulated assay)	4	-4.0
Cholesterol efflux capacity (cAMP stimulated assay)	4	-2.2
Cholesterol ester levels in large LDL	4	-3.0
Cholesterol ester levels in medium LDL	5	-2.9
Cholesterol ester levels in very large HDL	1	-2.9
Cholesterol, total	214	-8.3
Cholesteryl ester transfer protein levels	5	-2.1
Chronic back pain	6	-9.1
Chronic bronchitis and chronic obstructive pulmonary disease	43	-3.4
Chronic central serous retinopathy	5	-4.4
Chronic hepatitis B infection	12	-5.3
Chronic hepatitis C infection	6	-2.7
Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	997	-29.4
Chronic kidney disease	316	-5.4
Chronic kidney disease and serum creatinine levels	56	-9.0
Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes	14	-4.3
Chronic kidney disease in diabetes	6	-2.4
Chronic kidney disease in type 2 diabetes	22	-4.7
Chronic kidney disease (severe chronic kidney disease vs normal kidney function) in type 1 diabetes	2	0.0
Chronic lymphocytic leukemia	160	-12.9
Chronic mucus hypersecretion	6	-2.9
Chronic obstructive pulmonary disease	616	-5.2
Chronic obstructive pulmonary disease (moderate to severe)	63	-3.1
Chronic obstructive pulmonary disease or coronary artery disease (pleiotropy)	25	-3.3
Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	81	-3.3
Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)	122	-7.5
Chronic obstructive pulmonary disease-related biomarkers	60	-4.8
Chronic obstructive pulmonary disease (severe)	39	-3.7
Chronic periodontitis	8	-4.0
Chronic periodontitis (mean interproximal clinical attachment level)	36	-4.7
Chronic rhinosinusitis	29	-2.3
Chronic rhinosinusitis with nasal polyps	2	-3.3
Chronic sinus infection	72	-2.5
Chronic venous disease	2	-2.5
Chronotype	2504	-6.7
Cigarettes smoked per day (MTAG)	356	-3.1
Cingulate cortical amyloid beta load	8	-4.5
Circulating chemerin levels	15	-4.3
Circulating chromogranin peptide levels	29	-7.8
Circulating fibroblast growth factor 23 levels	104	-4.3
circulating leptin levels	46	-6.6
circulating leptin levels adjusted for BMI	16	-8.6
Circulating myeloperoxidase levels (plasma)	1	-2.7
Circulating myeloperoxidase levels (serum)	15	-4.0
Circulating odd-numbered chain saturated fatty acid levels (C15:0)	26	-3.2
Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0)	18	-2.8
Circulating odd-numbered chain saturated fatty acid levels (C17:0)	27	-3.2
Circulating odd-numbered chain saturated fatty acid levels (C19:0)	66	-5.4
Circulating odd-numbered chain saturated fatty acid levels (C23:0)	35	-4.8
Circulating phylloquinone levels	6	-4.0
Cisplatin-induced ototoxicity	53	-3.2
Classic bladder exstrophy	119	-2.6
Cleft lip	10	-1.7
Cleft lip with or without cleft palate	73	-5.5
Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction)	2	-7.1
Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction)	6	-3.1
Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)	35	-4.0
Cleft palate	75	-2.2
Clinical laboratory measurements	38	-2.5
Clopidogrel active metabolite levels	50	-6.1
Clostridium difficile infection in multiple myeloma	102	-3.7
Clozapine-induced agranulocytosis	154	-4.3
Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia	23	-3.6
Clozapine-induced cytotoxicity	50	-4.6
Cluster headache	6	-4.7
Cocaine dependence	93	-4.1
Coenzyme Q10 levels	51	-3.1
Coffee consumption	377	-4.2
Coffee consumption (cups per day)	22	-3.9
Cognitive ability	337	-9.8
Cognitive ability (MTAG)	483	-8.3
Cognitive decline (age-related)	102	-5.0
Cognitive decline rate in late mild cognitive impairment	181	-3.3
Cognitive empathy	375	-3.2
Cognitive flexibility	7	-2.9
Cognitive function	387	-6.4
Cognitive impairment test score	63	-7.4
Cognitive performance	1486	-4.6
Cognitive performance (MTAG)	2662	-5.5
Cognitive test performance	144	-5.6
Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement	15	-5.6
Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications	2	-1.7
Cold sores	125	-16.9
Colonoscopy-negative controls vs population controls	576	-3.6
Colorectal adenoma (advanced)	57	-3.1
Colorectal cancer	1135	-6.9
Colorectal cancer (alcohol consumption interaction)	2	-2.9
Colorectal cancer (aspirin and/or NSAID use interaction)	18	-5.5
Colorectal cancer (calcium intake interaction)	12	-2.9
Colorectal cancer (diet interaction)	66	-5.9
Colorectal cancer (oestrogen-progestogen hormone therapy interaction)	3	-6.7
Colorectal or endometrial cancer	160	-2.9
Common carotid intima-media thickness	52	-1.6
Common carotid intima-media thickness in HIV infection	44	-5.1
Common carotid intima-media thickness in HIV negative individuals	28	-3.2
Common traits (Other)	46	-6.7
Complete remission in asthma	2	-2.3
Conduct disorder	126	-3.7
Conduct disorder (maternal expressed emotions interaction)	56	-2.5
Conduct disorder (symptom count)	158	-3.3
Congenital heart disease (inherited effect)	58	-3.0
Congenital heart disease (maternal effect)	55	-2.5
Congenital heart malformation	20	-3.0
Congenital left-sided heart lesions	3	-2.4
Congenital left-sided heart lesions (maternal effect)	9	-2.5
Conotruncal heart defects	45	-4.4
Conotruncal heart defects (inherited effects)	45	-2.9
Conotruncal heart defects (maternal effects)	65	-2.5
Contrast sensitivity	4	-1.9
Corneal astigmatism	219	-2.7
Corneal curvature	70	-2.2
Corneal structure	186	-5.4
Coronary artery aneurysm in Kawasaki disease	67	-8.5
Coronary artery calcification	250	-4.7
Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes	416	-3.2
Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes	338	-3.5
Coronary artery calcified atherosclerotic plaque score in type 2 diabetes	137	-3.2
Coronary artery disease	1714	-7.7
Coronary artery disease and triglyceride levels (multivariate analysis)	4	-2.7
Coronary artery disease in type 1 diabetes	38	-2.0
Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)	158	-7.0
Coronary artery disease or ischemic stroke	31	-3.9
Coronary artery disease or large artery stroke	30	-4.0
Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction)	75	-3.6
Coronary heart disease	289	-4.3
Coronary restenosis	2	-3.6
Corrected insulin response adjusted for insulin sensitivity index	17	-3.8
Corrected insulin response	17	-3.8
Cortical amyloid beta load	97	-3.1
Cortical brain region measurements (area, volume and thickness)	12	-2.6
Cortical thickness	1	0.0
Corticobasal degeneration	7	-4.7
Corticosteroid-induced adrenal suppression (peak cortisol < 350 nmol/L)	7	-5.1
Corticosteroid-induced adrenal suppression (peak cortisol < 500 nmol/L)	7	-5.1
Cortisol levels (saliva)	40	-4.5
Cotinine glucuronidation	30	-2.7
Cough in response to angiotensin-converting enzyme inhibitor drugs	62	-3.9
C-peptide levels in type I diabetes	5	-2.8
Cranial base width	5	-4.8
Craniofacial microsomia	28	-3.2
C-reactive protein	61	-3.4
C-reactive protein and white blood cell count	34	-2.6
C-reactive protein levels	516	-5.7
C-reactive protein levels in ischemic stroke	15	-1.4
C-reactive protein levels or HDL-cholesterol levels (pleiotropy)	73	-5.0
C-reactive protein levels or LDL-cholesterol levels (pleiotropy)	66	-5.2
C-reactive protein levels or total cholesterol levels (pleiotropy)	69	-4.6
C-reactive protein levels or triglyceride levels (pleiotropy)	79	-3.7
Creatine kinase levels	110	-5.6
Creatinine levels	323	-3.6
Creatinine levels in ischemic stroke	19	-4.4
Creutzfeldt-Jakob disease	14	-2.9
Creutzfeldt-Jakob disease (sporadic)	4	-3.0
Creutzfeldt-Jakob disease (variant)	19	-3.4
Crohn's disease	1263	-28.8
Crohn's disease and celiac disease	13	-3.0
Crohn's disease and sarcoidosis (combined)	9	-5.0
Crohn's disease (indolent vs progressive)	69	-3.7
Crohn's disease (need for surgery)	28	-2.5
Crohn's disease-related phenotypes	31	-3.0
Crohn's disease (time to first abdominal surgery)	37	-6.0
Crohn's disease (time to progression)	75	-6.0
Crohn's disease (time to surgery)	7	-2.8
CSF tryptophan concentration in tuberculous meningitis	40	-4.9
CTACK levels	144	-4.5
Current cigarettes per day in chronic obstructive pulmonary disease	27	-2.7
Cutaneous malignant melanoma	80	-4.1
Cutaneous nevi	4	-2.5
Cutaneous squamous cell carcinoma	7	-3.2
Cystic fibrosis severity	51	-5.3
Cytomegalovirus antibody response	19	-5.7
Daytime nap	17	-3.9
Daytime sleepiness	4	-3.1
Daytime sleep phenotypes	394	-3.4
D-dimer levels	48	-2.4
DDT metabolite (p,p'-DDE levels)	5	-5.4
Decline in glucose metabolism in posterior cingulate cortex	5	-3.1
Deep ovarian and/or rectovaginal disease with dense adhesions	68	-6.8
Dehydroepiandrosterone sulphate levels	37	-5.2
Delayed reward discounting	72	-3.3
Deliberate self-harm	60	-8.7
Delta-5 desaturase activity	24	-2.8
Delta-5 desaturase activity response to n3-polyunsaturated fat supplement	12	-3.7
Delta-6 desaturase activity	14	-6.5
Dementia and core Alzheimer's disease neuropathologic changes	74	-2.7
Dementia with Lewy bodies	1	-2.1
Dengue shock syndrome	14	-3.0
Dental caries	383	-5.5
Dentate gyrus granule cell layer volume	14	-4.1
Dentate gyrus granule cell layer volume (corrected for total hippocampal volume)	1	-3.1
Dentate gyrus molecular layer volume	18	-3.7
Depressed affect	641	-3.5
Depression	1084	-4.0
Depression and alcohol dependence	3	-2.6
Depression (broad)	646	-5.4
Depression in response to interferon-based therapy in chronic hepatitis C	15	-2.9
Depression in smokers	105	-4.5
Depression (quantitative trait)	99	-4.6
Depressive and manic episodes in bipolar disorder	55	-2.4
Depressive episodes in bipolar disorder	70	-3.4
Depressive symptom improvement	28	-6.1
Depressive symptom measurement or major depressive disorder	9	-2.0
Depressive symptoms	1566	-6.7
Depressive symptoms (MTAG)	447	-4.0
Depressive symptoms (SSRI exposure interaction)	29	-3.0
Depressive symptoms (stressful life events interaction)	9	-2.2
Depressive symptoms x dependent stressful life events interaction (1df test)	53	-5.4
Depressive symptoms x dependent stressful life events interaction (2df test)	52	-3.1
Depressive symptoms x independent stressful life events interaction (1df test)	30	-4.1
Depressive symptoms x independent stressful life events interaction (2df test)	24	-3.7
Dermatomyositis or juvenile dermatomyositis	2	-3.4
Developmental dysplasia of the hip	9	-2.2
Developmental language disorder	4	-3.5
Developmental language disorder (linguistic errors)	6	-4.5
Diabetes (gestational)	75	-5.3
Diabetes (incident)	28	-2.4
Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)	1	-3.4
Diabetes mellitus	13	-2.1
Diabetes related insulin traits	5	-2.8
Diabetic kidney disease	235	-2.9
Diabetic kidney disease in diabetes (ESRD vs. no ESRD)	1	-3.1
Diabetic kidney disease in type 2 diabetes	13	-5.1
Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD)	18	-2.8
Diabetic macular edema in type 2 diabetes	2	0.0
Diabetic nephropathy in type 1 diabetes	8	-5.4
Diabetic retinopathy	126	-4.4
Diabetic retinopathy (all NPDR and PDR)	71	-3.8
Diabetic retinopathy (moderate NPDR and PDR)	35	-4.9
Dialysis-related mortality	80	-3.4
Diarrhoea-associated Entamoeba histolytica infection	1	-1.9
Diarrhoea in darapladib-treated cardiovascular disease (time to event)	4	-3.3
diarrhoeal disease at age 1 with doctor diagnosis	1	-2.4
diarrhoeal disease at age 2	2	-2.9
Diastolic blood pressure	2944	-17.0
Diastolic blood pressure (alcohol consumption interaction)	1	-1.7
Diastolic blood pressure (cigarette smoking interaction)	213	-2.4
Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)	1	0.0
Diastolic blood pressure night-to-day ratio in hypertension	20	-3.8
Diastolic blood pressure response to hydrochlorothiazide in hypertension	26	-3.2
Diastolic blood pressure x alcohol consumption interaction (2df test)	405	-6.4
Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)	173	-7.8
Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)	83	-3.1
Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	267	-3.7
Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)	2	-2.1
Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	184	-4.1
Diastolic blood pressure x sodium interaction (1df test)	13	-3.5
Diastolic blood pressure x sodium interaction (2df test)	4	-4.6
Dietary macronutrient intake	47	-5.4
Differentiated thyroid cancer	70	-3.6
Diffuse cutaneous systemic sclerosis	8	-3.2
Diffuse large B cell lymphoma	12	-3.2
Diffusing capacity of carbon monoxide	245	-4.6
Diffusing capacity of the lung for carbon monoxide traits	11	-3.1
Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)	55	-4.9
Digit length ratio	51	-8.6
Digit length ratio (left hand)	51	-8.6
Digit length ratio (right hand)	43	-8.8
Diisocyanate-induced asthma	553	-2.7
Disc degeneration (lumbar)	85	-3.8
Discordance in emotional problems in monozygotic twins	27	-3.9
Disease-free survival in breast cancer	13	-5.1
Disease progression in age-related macular degeneration	142	-3.4
Disease progression to choroidal neovascularization form in age-related macular degeneration	2	0.0
Disrupted circadian rhythm (low relative amplitude of rest-activity cycles)	8	-2.6
Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia	21	-3.6
Diverticular disease	546	-3.0
DNA methylation (parent-of-origin)	52	-3.3
DNA methylation (variation)	43	-2.8
DNA methylation variation (age effect)	1772	-4.4
Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer	37	-2.6
Double-edged eyelids	25	-2.0
Drinking behavior	2	-3.1
Drug experimentation measurement	7	-3.3
Drug-induced cholestatic/mixed liver injury	5	-2.1
Drug-induced liver injury	8	-1.9
Drug-induced liver injury (anti-tuberculosis drugs)	22	-3.4
Drug-induced liver injury (diclofenac)	50	-1.7
Drug-induced liver injury (flucloxacillin)	19	-4.3
Drug-induced liver injury (fluoroquinolones)	11	-2.7
Drug-induced liver injury (nitrofurantoin)	41	-2.2
Drug-induced liver injury (nonsteroidal anti-inflammatory drugs)	4	-2.9
Drug-induced liver injury (statins)	26	-3.3
Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)	23	-5.3
Duloxetine response in major depressive disorder ( change in symptom score)	11	-2.7
Duodenal ulcer	3	-3.3
Dupuytren's disease	171	-3.2
Dysmenorrheic pain	1	-2.2
Dysmenorrheic pain severity	27	-4.2
Dysphagia	39	-1.9
Early age at menarche	3	-2.1
Early childhood aggressive behavior	7	-2.7
Early diabetic kidney disease in diabetes	11	-5.4
Early onset atrial fibrillation	65	-5.7
Ear morphology	16	-5.3
Ease of getting up in the morning	323	-3.2
Eating disorder in bipolar disorder	6	-2.4
Eating disorders	71	-3.7
Eating disorders (purging via substances)	69	-3.8
Echocardiographic traits	25	-2.3
Economic and political preferences	100	-4.1
Economic and political preferences (environmentalism)	72	-3.0
Economic and political preferences (fairness)	54	-2.7
Economic and political preferences (feminism/equality)	86	-2.9
Economic and political preferences (immigration/crime)	15	-3.2
Economic and political preferences (time)	20	-4.8
Eczema	700	-16.5
Educational attainment	444	-5.1
Educational attainment (college completion)	99	-4.9
Educational attainment (MTAG)	6475	-10.4
Educational attainment (years of education)	8308	-12.5
EGFR mutation-positive lung adenocarcinoma	11	-3.3
Egg allergy	6	-3.0
Egg allergy (maternal genetic effects)	42	-4.3
Egg allergy (parent-of-origin effect)	6	-2.1
Ejection fraction	13	-5.6
Ejection fraction in Tripanosoma cruzi seropositivity	133	-3.9
Electrocardiographic conduction measures	30	-2.6
Electrocardiographic traits	135	-5.3
Electrodermal activity	118	-6.0
Electroencephalogram traits	169	-7.6
Electroencephalographic traits in alcoholism	25	-3.2
Elevated fasting plasma glucose	8	-3.5
Elevated serum carcinoembryonic antigen levels	4	-2.6
Emotional dysregulation	4	-2.2
Empathy quotient	33	-2.3
Emphysema distribution in smoking	32	-3.8
Emphysema imaging phenotypes	130	-3.2
Emphysema-related traits	24	-2.3
Endometrial cancer	105	-4.2
Endometrial cancer (endometrioid histology)	80	-4.8
Endometrial cancer (Non-endometrioid histology)	9	-1.2
Endometrial endometrioid carcinoma	6	-2.8
Endometrioid ovarian cancer	1	-2.8
Endometriosis	327	-7.8
Endometriosis or endometrial cancer (pleiotropy)	9	-3.3
End-stage coagulation	40	-4.3
End-stage renal disease	49	-3.5
End stage renal disease in APOL1 risk genotype-negative individuals	44	-6.2
End-stage renal disease in Type 1 diabetics	6	-3.5
End-stage renal disease in type 2 diabetes	4	-3.7
End stage renal disease x APOL1 genotype interaction	15	-2.4
Energy expenditure (24h)	16	-2.9
Energy expenditure	32	-2.5
Energy intake	6	-4.2
Enteric fever	2	-2.2
Entorhinal cortical thickness	43	-3.6
Entorhinal cortical thickness (Alzheimer's disease interaction)	1	-3.1
Entorhinal cortical volume	3	-2.5
Eosinophil counts	2527	-44.5
Eosinophilic esophagitis	43	-3.6
Eosinophilic esophagitis (pediatric)	55	-3.6
Eosinophil percentage of granulocytes	440	-17.3
Eosinophil percentage of white cells	421	-20.4
Eotaxin levels	121	-3.4
Epilepsy	76	-4.4
Epilepsy and lamotrigine-induced maculopapular eruptions	205	-5.4
Epilepsy (remission after treatment)	23	-5.5
Epirubicin-induced leukopenia	6	-3.6
Epithelial ovarian cancer	367	-7.0
Epstein-Barr virus copy number in lymphoblastoid cell lines	159	-2.4
Epstein-Barr virus immune response (EBNA-1)	12	-6.0
Epstein Barr virus nuclear antigen 1 IgG levels	2	-3.2
Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis	10	-3.3
Erectile dysfunction	109	-4.7
Erectile dysfunction and prostate cancer treatment	73	-5.9
Erectile dysfunction in type 1 diabetes	5	-2.1
Erosive tooth wear (severe vs none or mild)	102	-7.3
Erosive tooth wear (severe vs non-severe)	352	-6.3
Erythema nodosum in inflammatory bowel disease	22	-4.5
Erythrocyte cadmium concentration	43	-3.5
Erythrocyte cadmium concentration in never smokers	4	-2.8
E-selectin levels	4	-3.1
Esophageal adenocarcinoma	21	-3.9
Esophageal adenocarcinoma x gastroesophageal reflux disease interaction	28	-3.4
Esophageal adenocarcinoma x pack-years of smoking exposure interaction	1	-2.0
Esophageal adenocarcinoma x smoking interaction	60	-7.1
Esophageal cancer	44	-3.1
Esophageal cancer (alcohol interaction)	19	-3.8
Esophageal squamous cell carcinoma	16	-4.5
Essential tremor	59	-4.5
Esterified cholesterol levels	1	-3.6
Estimated glomerular filtration rate	1760	-7.7
Estimated glomerular filtration rate after 1 year in renal transplantation (donor effect)	19	-2.7
Estimated glomerular filtration rate after 1 year in renal transplantation (recipient effect)	10	-2.5
Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect)	35	-3.5
Estimated glomerular filtration rate after 5 years in renal transplantation (recipient effect)	53	-3.2
Estimated glomerular filtration rate change in renal transplantation (donor effect)	3	-2.1
Estimated glomerular filtration rate change in renal transplantation (recipient effect)	48	-3.9
Estimated glomerular filtration rate in coronary artery disease and impaired kidney function	3	-2.5
Estradiol levels	74	-4.0
Estradiol plasma levels (breast cancer)	73	-2.2
Estrogen receptor status in HER2 negative breast cancer	4	-3.7
Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer	44	-4.6
Estrone levels	3	-5.0
Eudaimonic well-being	50	-3.9
Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy	4	-3.3
Ewing sarcoma	16	-5.0
Excessive daytime sleepiness	25	-3.6
Excessive hairiness	19	-6.6
Excessive sweating	9	-3.0
Executive function in ADHD	17	-10.1
Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder	8	-5.5
Exercise treadmill test traits	5	-2.8
Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease	14	-3.2
Exhaled nitric oxide levels	43	-4.1
Exhaled nitric oxide output	35	-4.1
Experiencing mood swings	269	-3.3
Exploratory eye movement dysfunction in schizophrenia (cognitive search score)	32	-3.7
Exploratory eye movement dysfunction in schizophrenia (mean eye scanning length)	1	0.0
Exploratory eye movement dysfunction in schizophrenia (number of eye fixations)	83	-3.3
Exploratory eye movement dysfunction in schizophrenia (responsive search score)	41	-4.6
Exploratory eye movement dysfunction in schizophrenia (total eye scanning length)	84	-2.9
Expressive vocabulary in infants	76	-2.6
Extraversion	28	-4.0
Extremely high intelligence	175	-3.3
Exudative age-related macular degeneration	4	-2.2
Eyebrow thickness	43	-4.6
Eye color	35	-3.4
Eye color (brightness)	8	-4.7
Eye color (saturation)	19	-3.9
Eye length	13	-7.2
Eye morphology	78	-5.3
Eye movement (horizontal position gain)	19	-3.5
Eye movement in schizophrenia (horizontal position gain)	52	-3.8
Facial depth	6	-3.2
Facial emotion recognition	18	-4.9
Facial emotion recognition (angry faces)	40	-2.8
Facial emotion recognition (fearful faces)	5	-5.0
Facial emotion recognition (happy faces)	1	-2.8
Facial emotion recognition (sad faces)	2	-2.8
Facial morphology	32	-4.2
Facial morphology (factor 10, width of nasal floor)	41	-4.7
Facial morphology (factor 11, projection of the nose)	82	-5.4
Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface)	33	-2.8
Facial morphology (factor 13, vertical position of alar curvature relative to upper lip)	35	-6.9
Facial morphology (factor 14, intercanthal width)	56	-3.6
Facial morphology (factor 15, philtrum width)	36	-3.9
Facial morphology (factor 16)	38	-3.4
Facial morphology (factor 17, height of vermillion upper lip)	47	-3.3
Facial morphology (factor 18)	49	-4.1
Facial morphology (factor 19)	143	-2.8
Facial morphology (factor 1, breadth of lateral portion of upper face)	53	-3.8
Facial morphology (factor 20)	67	-5.0
Facial morphology (factor 21, depth of nasal alae)	42	-3.8
Facial morphology (factor 22)	62	-2.6
Facial morphology (factor 23)	33	-3.9
Facial morphology (factor 2, vertical position of orbits relative to midface)	36	-3.0
Facial morphology (factor 3, length of philtrum)	15	-2.3
Facial morphology (factor 4, facial height related to vertical position of gnathion)	22	-8.5
Facial morphology (factor 5, width of mouth relative to central midface)	59	-4.7
Facial morphology (factor 6, height of vermillion lower lip)	41	-2.6
Facial morphology (factor 7, width of cartilaginous portion of nose)	47	-3.5
Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion)	48	-3.3
Facial morphology (factor 9, facial height related to vertical position of nasion)	40	-3.0
facial morphology traits (multivariate analysis)	19	-3.8
Facial pigmentation	1	-2.5
Facial wrinkles	24	-4.1
Factor VII	15	-3.4
Factor VII activity	32	-2.2
Factor VIII levels	39	-6.9
Familial hepatitis B virus-related hepatocellular carcinoma	31	-2.8
Familial lung adenocarcinoma	72	-5.2
Familial lung cancer	12	-2.3
Familial squamous cell lung carcinoma	202	-5.9
Family history of Alzheimer's disease	112	-15.0
Fast beta electroencephalogram	29	-5.0
Fasting blood glucose	220	-3.7
Fasting blood glucose adjusted for BMI	10	-4.2
Fasting blood glucose (BMI interaction)	155	-4.0
Fasting blood insulin	104	-3.7
Fasting blood insulin (BMI interaction)	124	-3.2
Fasting glucose in pregnancy (gestational week 14-16)	2	-2.8
Fasting insulin (dietary factor interaction)	97	-4.2
Fasting plasma glucose	149	-5.0
Fasting plasma glucose (childhood)	3	-3.9
Fat body mass	15	-2.6
Fat distribution (HIV)	26	-3.7
Fat-free mass	787	-8.4
Fatty acid desaturase activity (adipose tissue)	1	-3.6
Fatty acid desaturase activity (serum)	2	-5.0
F-cell distribution	23	-6.6
F-cell distribution in sickle cell anaemia	54	-2.1
Fear of medical pain (dental)	3	-3.0
Fear of minor pain	15	-2.6
Fear of pain	3	-2.6
Fear of severe pain	12	-3.4
Febrile seizures (MMR vaccine-related)	11	-2.5
Feeling fed-up	239	-12.0
Feeling guilty	141	-42.9
Feeling hurt	248	-3.8
Feeling lonely	43	-4.6
Feeling miserable	275	-3.3
Feeling nervous	156	-3.0
Feeling tense	154	-4.9
Feeling worry	308	-3.6
Femoral neck bone geometry	1	0.0
Femoral neck bone geometry and menarche (age at onset)	21	-4.7
Femoral neck bone mineral density	433	-3.9
Femoral neck length	19	-3.9
Fetal hemoglobin levels	26	-3.8
Fetal hemoglobin levels in sickle cell anemia	6	-3.8
FEV1	1176	-8.5
Fibrinogen	16	-4.8
Fibrinogen levels	112	-6.6
Fibroblast growth factor basic levels	65	-2.6
Focal epilepsy (with hippocampal sclerosis)	15	-3.5
Folate pathway vitamin levels	23	-1.9
Folding of antihelix	28	-4.1
Follicular lymphoma	46	-8.5
Follicule stimulating hormone	10	-5.6
Follicule stimulating hormone levels in polycystic ovary syndrome	73	-4.8
Food addiction	84	-6.2
Food allergy	26	-4.1
Food allergy (maternal genetic effects)	69	-3.3
Food allergy (parent-of-origin effect)	3	-6.0
Food antigen IgG levels	19	-2.5
Foot ulcer and neuropathy in diabetes	87	-3.9
Forced expiratory volume in 1 second (occupational environmental exposures interaction)	75	-3.2
Forearm bone mineral density	3	-5.2
Forehead morphology	9	-1.9
Formal thought disorder in schizophrenia	37	-3.9
Fractional excretion of metabolites in chronic kidney disease	4	-2.2
Fractional excretion of uric acid	3	-4.1
Fractional exhaled nitric oxide (childhood)	82	-3.9
Fractional exhaled nitric oxide levels	47	-4.5
Fractional shortening	16	-5.3
Fractures	148	-4.8
Fractures (vertebral)	8	-4.2
Freckles	17	-4.2
Free cholesterol levels	1	-3.6
Free cholesterol levels in large LDL	2	-3.3
Free cholesterol levels in medium HDL	1	-2.9
Free thyroxine concentration	110	-3.3
Frontotemporal dementia	33	-4.6
Frontotemporal dementia (age at onset)	8	-4.8
Frontotemporal dementia with GRN mutation	62	-2.6
Frontotemporal dementia with GRN mutation (age at onset)	11	-4.1
Fructosamine levels	22	-4.2
Fuchs's corneal dystrophy	13	-4.7
Full scale intelligence quotient (cesarean section interaction)	8	-2.9
Fulminant type 1 diabetes	4	-2.4
Functional impairment in major depressive disorder, bipolar disorder and schizophrenia	27	-2.5
Gait rhythm	19	-7.3
Gait speed in old age	158	-3.9
Gait variability	1	-2.3
Gallbladder cancer	66	-2.5
Gallstone disease	55	-3.8
Gambling	8	-3.7
Gamma glutamyl transferase levels	180	-11.9
Gamma glutamyl transferase levels in excessive alcohol consumption	31	-4.6
Gamma glutamyl transferase levels in low alcohol consumption	56	-4.7
Gamma glutamyl transpeptidase	5	-4.5
Gastric cancer	35	-3.0
Gastric parietal cell autoantibody levels in type 1 diabetes	2	-4.3
Gastritis	53	-5.3
Gastroesophageal reflux disease	15	-2.2
Gaucher disease severity	8	-3.6
Gemcitabine-induced early high-grade neutropenia in pancreatic cancer	61	-4.4
Gene methylation in lung tissue	1	-1.9
General cognitive ability	4743	-12.8
General factor of neuroticism	852	-5.1
General glucose level in pregnancy (gestational week 30-32)	1	0.0
Generalized epilepsy	162	-3.3
General risk tolerance (MTAG)	1771	-5.9
Gestational age at birth (child effect)	33	-4.9
Gestational age at birth in labor-initiated deliveries (child effect)	53	-3.0
Gestational age at birth in labor-initiated deliveries (maternal effect)	9	-2.9
Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect)	19	-4.2
Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect)	38	-4.8
Gestational age at birth (maternal effect)	44	-3.2
Giant cell arteritis	19	-7.2
GIP levels in response to oral glucose tolerance test (120 minutes)	10	-6.2
Glaucoma	185	-7.9
Glaucoma (high intraocular pressure)	9	-3.3
Glaucoma (low intraocular pressure)	13	-2.5
Glaucoma (primary angle closure)	33	-4.7
Glaucoma (primary open-angle)	341	-4.4
Glioblastoma	35	-4.9
Glioblastoma (age-stratified)	25	-5.1
Glioma	105	-6.0
Glioma (high-grade)	1	-1.7
Global electrical heterogeneity phenotypes	63	-5.8
Glomerular filtration rate	321	-3.5
Glomerular filtration rate change in heart transplantation	13	-2.9
Glomerular filtration rate (creatinine)	378	-3.3
Glomerular filtration rate in chronic kidney disease	90	-3.7
Glomerular filtration rate in diabetes	14	-5.5
Glomerular filtration rate in non diabetics (creatinine)	144	-4.1
Glomerular filtration rate in type 2 diabetes	29	-2.3
GLP-1 levels in response to oral glucose tolerance test (fasting)	2	-7.3
Glucocorticoid-induced osteonecrosis	42	-3.7
Glucocorticoid-induced osteonecrosis (age 10 years and older)	24	-2.8
Glucocorticoid-induced osteonecrosis (time dependent analysis)	7	-2.5
Glucose homeostasis traits	245	-3.9
Glycated hemoglobin levels	386	-5.3
Glycated hemoglobin levels in type 1 diabetes	10	-2.1
Glycemic traits	10	-4.6
Glycemic traits (multi-trait analysis)	2	-1.8
Glycemic traits (pregnancy)	12	-5.2
Glycerophospholipid levels	43	-5.5
Glycine levels	116	-4.2
Gout	162	-5.5
Gout in chronic kidney disease	1	0.0
Gout vs. Hyperuricemia	37	-2.3
Granulocyte-colony stimulating factor levels	53	-3.5
Granulocyte count	387	-13.1
Granulocyte percentage of myeloid white cells	522	-35.2
Graves' disease	87	-5.3
Gray matter volume (schizophrenia interaction)	4	-2.7
Growth-regulated protein alpha levels	130	-7.0
Gut microbiome composition (summer)	256	-2.5
Gut microbiome composition (summer and winter)	95	-2.5
Gut microbiome composition (winter)	166	-2.6
Gut microbiota (bacterial taxa)	336	-3.4
Gut microbiota (beta diversity)	65	-9.5
Gut microbiota (functional units)	192	-2.4
Hair color	2038	-7.4
Hair greying	22	-3.3
Hair morphology	22	-4.8
Hair morphology traits	2	-2.0
Hair shape	21	-3.4
Handedness	15	-2.1
Handedness (Left-handed vs. non-left-handed)	1	-2.2
Hand grip strength	536	-4.9
Hashimoto thyroiditis	1	-1.6
Hashimoto thyroiditis versus Graves' disease	9	-1.6
HATA volume	7	-3.1
HbA2 levels	18	-5.4
HDL cholesterol	791	-9.7
HDL cholesterol and triglyceride levels	68	-4.7
HDL cholesterol and triglyceride levels (pleiotropy)	11	-2.2
HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes	61	-3.6
HDL Cholesterol in HIV-infection	4	-2.2
HDL cholesterol levels	485	-7.1
HDL Cholesterol - Triglycerides (HDLC-TG)	32	-5.2
HDL cholesterol x physical activity interaction (2df test)	98	-5.1
Headache	112	-4.2
Head circumference (infant)	11	-2.4
Healthspan	35	-2.6
Hearing function	8	-2.9
Hearing impairment	1	-3.4
Heart failure	147	-5.7
Heart rate	283	-8.6
Heart rate increase in response to exercise	30	-6.0
Heart rate response to beta blockers	2	-2.9
Heart rate response to beta blockers (atenolol add-on therapy)	106	-3.3
Heart rate response to beta blockers (atenolol monotherapy)	141	-3.8
Heart rate response to exercise	91	-4.6
Heart rate response to recovery post exercise (10 sec)	24	-6.3
Heart rate response to recovery post exercise (20 sec)	42	-5.6
Heart rate response to recovery post exercise (30 sec)	46	-5.5
Heart rate response to recovery post exercise (40 sec)	30	-6.0
Heart rate response to recovery post exercise (50 sec)	52	-5.3
Heart rate response to recovery post exercise	197	-30.7
Heart rate variability traits	75	-4.1
Heart rate variability traits (pvRSA/HF)	47	-5.4
Heart rate variability traits (RMSSD)	42	-5.6
Heart rate variability traits (SDNN)	63	-5.1
Heavy vaginal discharge	9	-5.9
Hedonic well-being	14	-1.9
Heel bone mineral density	8416	-21.0
Height	10558	-14.4
Height adjusted BMI	23	-7.2
Helix rolling	8	-3.5
Helping behaviour (self reported)	11	-3.9
Hematocrit	408	-7.7
Hematological and biochemical traits	49	-2.7
Hematological parameters	12	-6.9
Hematology traits	23	-6.0
Hematoma volume in lobar spontaneous intracerebral hemorrhage	2	-2.4
Hemoglobin	60	-5.4
Hemoglobin A1c levels	168	-6.5
Hemoglobin A2 levels in sickle cell anemia	11	-3.0
Hemoglobin concentration	322	-6.6
Hemoglobin levels	52	-6.8
Hemostatic factors and hematological phenotypes	161	-4.8
Hen's egg allergy	1	-1.6
Hepatic lipid content in extreme obesity	2	-2.8
Hepatitis	26	-3.4
Hepatitis A	67	-6.1
Hepatitis B	152	-3.4
Hepatitis B surface antigen seroclearance in chronic hepatitis B infection	6	-5.2
Hepatitis B vaccine response	12	-6.0
Hepatitis C induced liver cirrhosis	3	-3.2
Hepatitis C induced liver fibrosis	6	-3.1
Hepatitis C (spontaneous viral clearance)	10	-5.5
Hepatocellular carcinoma	25	-2.2
Hepatocellular carcinoma in hepatitis B infection	18	-5.0
Hepatocellular carcinoma in hepatitis C infection	10	-5.5
Hepatocyte growth factor levels	75	-3.9
Hepcidin/ferritin ratio	310	-4.9
Hepcidin levels	71	-3.4
Hepcidin/transferrin saturation ratio	11	-3.4
HER2 status in breast cancer	11	-2.9
Heroin dependence	109	-4.9
Heschl's gyrus morphology	191	-4.2
High altitude adaptation	14	-5.0
High density lipoprotein cholesterol levels	934	-9.8
Highest math class taken	1817	-4.2
Highest math class taken (MTAG)	5523	-14.6
High fetal hemoglobin in sickle cell disease	10	-3.1
High-grade serous ovarian cancer	17	-3.3
High IL-1beta levels in gingival crevicular fluid	130	-11.6
High light scatter reticulocyte count	554	-10.5
High light scatter reticulocyte percentage of red cells	489	-13.3
Hip bone size	63	-4.8
Hip circumference	531	-5.0
Hip circumference adjusted for BMI	526	-4.8
Hip circumference (psychosocial stress interaction)	14	-2.1
Hip geometry	147	-3.1
Hip minimal joint space width	62	-5.2
Hippocampal atrophy	164	-4.1
Hippocampal sclerosis	32	-4.3
Hippocampal subfield CA1 volume	13	-2.9
Hippocampal subfield CA1 volume (corrected for total hippocampal volume)	1	-3.1
Hippocampal subfield CA3 volume	13	-2.9
Hippocampal subfield CA4 volume	14	-4.1
Hippocampal tail volume	52	-2.3
Hippocampal tail volume (corrected for total hippocampal volume)	39	-3.4
Hippocampal volume	143	-2.1
Hippocampal volume in Alzheimer's disease dementia	22	-2.2
Hippocampal volume in mild cognitive impairment	23	-3.8
Hippocampal volume in normal cognition	2	-2.1
Hip shape (DXA scan)	154	-4.4
Hirschsprung disease	55	-3.3
HIV-1 control	138	-3.9
HIV-1 progression	12	-2.0
HIV-1 susceptibility	27	-3.0
HIV-1 viral setpoint	186	-3.1
HIV-associated dementia	34	-2.6
HIV-associated neurocognitive disorder	2	-1.9
HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)	10	-4.5
HIV-associated neurocognitive disorder (mild neurocognitive disorder)	47	-4.5
HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)	16	-2.8
Hoarding	30	-2.7
Hodgkin's lymphoma	141	-12.1
Homeostasis model assessment of beta-cell function	8	-2.5
Homeostasis model assessment of beta-cell function (dietary factor interaction)	26	-2.9
Homeostasis model assessment of insulin resistance	4	-3.4
Homeostasis model assessment of insulin resistance (dietary factor interaction)	97	-4.2
Hormone measurements	18	-5.2
Household income	5	-3.6
HPV seropositivity	15	-5.1
Huntington's disease progression	32	-2.3
Hyperactive-impulsive symptoms	42	-2.6
Hyperemesis gravidarum	1	0.0
Hyperopia	21	-4.4
Hypersomnia during a major depressive episode in bipolar disorder	1	-3.6
Hypersomnia (HLA-DQB1*06:02 negative)	14	-2.4
Hypertension	681	-5.1
Hypertension risk in short sleep duration	5	-3.3
Hyperthyroidism	55	-4.4
Hypertriglyceridemia	21	-4.0
Hypospadias	106	-5.3
Hypothyroidism	594	-10.9
Idiopathic dilated cardiomyopathy	363	-26.4
Idiopathic inflammatory myopathy	2	-2.7
Idiopathic intracranial hypertension	62	-3.5
Idiopathic membranous nephropathy	3	-4.0
Idiopathic osteonecrosis of the femoral head	47	-4.0
Idiopathic pulmonary fibrosis	19	-6.7
IgA levels	14	-2.8
IgA nephropathy	39	-8.2
IgE grass sensitization	63	-4.0
IgE levels	3	-4.6
IgE levels in asthmatics	16	-3.2
IgE levels in asthmatics (D.f. specific)	22	-3.5
IgE levels in asthmatics (D.p. specific)	33	-4.4
IgG1 response to Plasmodium falciparum antigen (GLURP)	7	-3.1
IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis)	3	-3.2
IgG digalactosylation phenotypes (multivariate analysis)	17	-3.4
IgG disialylation phenotypes (multivariate analysis)	3	-3.2
IgG fucosylation phenotypes (multivariate analysis)	17	-3.4
IgG galactosylation phenotypes (multivariate analysis)	19	-3.3
IgG glycosylation	1516	-3.3
IgG glycosylation patterns	99	-7.2
IgG levels	20	-3.8
IgG monogalactosylation phenotypes (multivariate analysis)	17	-3.4
IgG monosialylation phenotypes (multivariate analysis)	17	-3.4
IgG N-glycosylation phenotypes (multivariate analysis)	19	-3.3
IgG sialylation phenotypes (multivariate analysis)	17	-3.4
IgM levels	26	-5.7
Ileal carcinoids	51	-4.8
Illicit drug use	31	-7.7
Immature fraction of reticulocytes	400	-13.4
Immune reponse to smallpox (secreted IFN-alpha)	74	-2.9
Immune reponse to smallpox (secreted IL-10)	68	-3.1
Immune reponse to smallpox (secreted IL-12p40)	64	-4.3
Immune reponse to smallpox (secreted IL-1beta)	21	-5.0
Immune reponse to smallpox (secreted IL-2)	75	-3.9
Immune reponse to smallpox (secreted TNF-alpha)	29	-3.0
Immune response to anthrax vaccine	16	-2.5
Immune response to measles-mumps-rubella vaccine	83	-2.2
Immune response to smallpox vaccine (IL-6)	315	-3.3
Immunoglobulin A	34	-4.6
Immunoglobulin A vasculitis	108	-3.7
Immunoglobulin G index levels in multiple sclerosis	8	-4.7
Immunoglobulin light chain (AL) amyloidosis	1	0.0
Immunoglobulin light chain (AL) amyloidosis (heart and kidney involvement)	1	0.0
Immunoglobulin light chain (AL) amyloidosis (liver involvement)	9	-1.9
Immunoglobulin measurement (zinc sulfate turbidity test)	1	-1.7
Impulsivity	3	-2.1
Impulsivity (attentional)	7	-2.2
Impulsivity (motor)	9	-3.9
Impulsivity (non-planning)	7	-2.0
Inattentive symptoms	83	-2.8
Incident atrial fibrillation	62	-5.7
Incident coronary heart disease	1	0.0
Incident myocardial infarction	16	-1.7
Incremental insulin	2	-1.8
Infant, child and juvenile death in continuous marriage (proportion of children died <15 years)	22	-2.3
Infant, child and juvenile death (proportion of children died <15 years)	4	-2.3
Infantile hypertrophic pyloric stenosis	23	-3.1
Infant length	63	-5.8
Inflammatory biomarkers	77	-2.8
Inflammatory bowel disease	1075	-26.2
Inflammatory bowel disease (early onset)	6	-10.5
Inflammatory skin disease	284	-4.2
Influenza A (H1N1) infection	16	-2.5
Influenza A (H1N1) severity	41	-3.9
Information processing speed	146	-4.1
Inguinal hernia	55	-8.8
Inhibitory control	33	-4.7
Initial alcohol sensitivity	158	-3.3
Initial pursuit acceleration	160	-2.9
Initial pursuit acceleration in psychotic disorders	78	-2.7
Insomnia	2187	-6.5
Insomnia (caffeine-induced)	40	-2.7
Insomnia complaints	5	-3.9
Insomnia complaints (continuous)	3	-4.9
Insomnia complaints (dichotomous)	3	-4.9
Insomnia symptoms (never/rarely vs. sometimes/usually)	239	-3.3
Insomnia symptoms (never/rarely vs. usually)	273	-2.9
Insulin disposition index	16	-3.9
Insulin levels adjusted for BMI	2	-1.8
Insulin levels in response to oral glucose tolerance test (fasting)	10	-2.5
Insulin levels	2	-1.8
Insulin-like growth factors	13	-4.0
Insulin resistance/response	15	-4.8
Insulin secretion rate	31	-4.4
Insulin sensitivity index	8	-4.0
Intelligence	2558	-7.4
Intelligence (childhood)	12	-3.5
Intelligence (MTAG)	2216	-9.1
Interferon alpha levels in systemic lupus erythematosus	41	-3.5
Interferon gamma-induced protein 10 levels	133	-4.3
Interferon gamma levels	54	-5.6
Interleukin-10 levels	101	-3.8
Interleukin-12p70 levels	93	-4.6
Interleukin-13 levels	48	-4.9
Interleukin-16 levels	47	-5.4
Interleukin-17 levels	82	-3.4
Interleukin-18 levels	142	-2.4
Interleukin-1-beta levels	19	-2.6
Interleukin-1-receptor antagonist levels	32	-3.7
Interleukin-2 levels	89	-3.2
Interleukin-2 receptor antagonist levels	96	-4.3
Interleukin-4 levels	69	-4.6
Interleukin-5 levels	28	-2.7
Interleukin-6 levels	146	-15.9
Interleukin-6 (red blood cell fatty acid level interaction)	48	-4.1
Interleukin-7 levels	106	-22.4
Interleukin-8 levels	33	-3.8
Interleukin-9 levels	42	-3.6
Interstitial lung disease	18	-2.4
Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)	38	-4.4
Intracranial aneurysm	268	-6.2
Intracranial volume	84	-5.2
Intra-individual response time variability (selective attention)	17	-7.1
Intraocular pressure	1728	-5.7
Invasive epithelial ovarian cancer	19	-3.2
Iris characteristics	12	-3.7
Iris color (a* coordinate)	199	-3.8
Iris color (b* coordinate)	156	-4.8
Iris color (L* coordinate)	158	-5.0
Iris heterochromicity	168	-4.0
Iron deficiency	5	-4.5
Iron status biomarkers	83	-5.7
Iron status biomarkers (ferritin levels)	22	-6.9
Iron status biomarkers (iron levels)	41	-3.5
Iron status biomarkers (total iron binding capacity)	23	-4.2
Iron status biomarkers (transferrin levels)	19	-8.8
Iron status biomarkers (transferrin saturation)	29	-6.3
Irritable bowel syndrome	94	-3.4
Irritable mood	338	-3.2
Ischemic stroke	167	-4.5
Ischemic stroke (cardioembolic)	105	-6.0
Ischemic stroke (large artery atherosclerosis)	32	-6.4
Ischemic stroke (small-vessel)	26	-4.2
Ischemic stroke (undetermined subtype)	2	-5.0
Isovolumetric relaxation time	54	-2.0
Itch intensity from mosquito bite	603	-5.4
Itch intensity from mosquito bite adjusted by bite size	868	-4.8
Job-related exhaustion	4	-2.9
Job-related exhaustion in shift workers	1	-2.0
Joint damage progression in ACPA-negative rheumatoid arthritis	2	-1.9
Joint mobility (Beighton score)	62	-7.4
JT interval (sulfonylurea treatment interaction)	156	-4.1
Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)	73	-4.4
Juvenile osteochondritis dissecans	24	-2.3
Kashin-Beck disease	13	-2.8
Kawasaki disease	110	-11.6
Keloid	11	-3.5
Kidney disease (early stage) in type 1 diabetes	9	-2.7
Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes	7	-2.2
Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes	2	-1.6
Kidney disease (late stage) in type 1 diabetes	3	-3.9
Kidney function decline traits	3	-2.1
Kidney stones	12	-2.7
Knee osteoarthritis	53	-3.4
Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis	3	-3.7
Lack of perseverance	6	-2.1
Lack of premeditation	12	-2.9
Lactate dehydrogenase levels	20	-5.3
Language impairment in frontotemporal lobe dementia	8	-2.5
Language performance in older adults (adjusted for episodic memory)	4	-3.5
Lapatinib-induced hepatotoxicity	21	-5.4
Large artery stroke	46	-3.2
Large B-cell lymphoma	8	-5.8
Large HDL particle concentration	14	-5.8
Large LDL particle concentration	4	-3.0
Laryngeal squamous cell carcinoma	8	-4.8
Late diabetic kidney disease in type 2 diabetes	13	-3.6
Latent autoimmune diabetes	3	-2.7
Late-onset Alzheimer's disease	260	-3.1
Late-onset myasthenia gravis	20	-2.9
Laterality in neovascular age-related macular degeneration	28	-3.3
Lateral ventricular volume in normal aging	24	-3.2
LDL cholesterol	349	-7.6
LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes	6	-2.6
LDL cholesterol levels	194	-10.1
LDL cholesterol x physical activity interaction (1df test)	1	-2.3
LDL cholesterol x physical activity interaction (2df test)	65	-9.5
LDL peak particle diameter (total fat intake interaction)	133	-2.9
Lead levels in blood	77	-4.2
Lean body mass	143	-4.0
Left atrial antero-posterior diameter	48	-3.0
Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction)	3	-2.4
Left superior temporal gyrus thickness (schizophrenia interaction)	34	-3.0
Left ventricle diastolic internal dimension	15	-5.4
Left ventricle systolic dysfunction	43	-5.9
Left ventricle wall thickness	94	-6.4
Left ventricular function change in anthracycline treatment	12	-3.2
Left ventricular internal dimension in diastole	20	-5.0
Left ventricular internal dimension in systole	20	-5.0
Left ventricular mass	24	-3.8
Left ventricular obstructive tract defect (inherited effect)	76	-4.1
Left ventricular obstructive tract defect (maternal effect)	42	-2.8
Leishmaniasis (visceral)	2	-3.3
Leisure-time exercise behaviour	8	-2.7
Leisure-time exercise behaviour (age-stratified)	1	0.0
Length of menstrual cycle	4	-4.1
Lentiform nucleus volume	23	-3.5
Leprosy	156	-8.2
Lewy body disease	75	-4.4
Life satisfaction	984	-3.4
Lifespan	2	-3.8
Life threatening arrhythmia	16	-6.7
Lifetime average cigarettes per day in chronic obstructive pulmonary disease	76	-2.9
Light vs. dark hair color	60	-6.0
Limited cutaneous systemic scleroderma	24	-2.6
Lipid metabolism phenotypes	66	-4.5
Lipid traits	46	-5.8
Lipid traits (pleiotropy) (HIPO component 1)	34	-4.6
Lipid traits (pleiotropy) (HIPO component 2)	2	-4.4
Lip morphology	2	-2.9
Lipoprotein (a) - cholesterol levels	15	-2.2
Lipoprotein (a) levels	102	-5.1
Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms	19	-3.2
Lipoprotein-associated phospholipase A2 activity and mass	20	-8.9
Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	8	-3.1
Lipoprotein phospholipase A2 activity in cardiovascular disease	66	-5.6
Liver disease severity in Alagille syndrome	5	-3.5
Liver enzyme levels	10	-2.6
Liver enzyme levels (alanine transaminase)	90	-3.3
Liver enzyme levels (alkaline phosphatase)	21	-4.0
Liver enzyme levels (aspartate transaminase)	54	-2.9
Liver enzyme levels (gamma-glutamyl transferase)	75	-4.0
Liver fibrosis in pediatric non-alcoholic fatty acid liver disease	2	-5.0
Liver fibrosis severity in HIV/hepatitis C co-infection	51	-2.7
Liver injury in anti-tuberculosis drug treatment	15	-2.5
Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis	40	-4.3
Liver transplant-free survival in primary sclerosing cholangitis (time to event)	83	-5.2
Lobe attachment	7	-4.1
Lobe attachment (rater scored)	25	-4.8
Lobe attachment (rater-scored or self-reported)	862	-8.3
Lobe size	17	-5.2
Lobular breast cancer (menopausal hormone therapy interaction)	5	-4.0
Local histogram emphysema pattern	29	-2.5
Logical memory (delayed recall)	8	-2.2
Logical memory (delayed recall) in Alzheimer's disease dementia	5	-9.7
Logical memory (delayed recall) in mild cognitive impairment	9	-4.2
Logical memory (delayed recall) in normal cognition	49	-3.0
Logical memory (immediate recall)	8	-2.2
Logical memory (immediate recall) in Alzheimer's disease dementia	19	-2.7
Logical memory (immediate recall) in mild cognitive impairment	1	-1.7
Logical memory (immediate recall) in normal cognition	18	-3.1
Loneliness	197	-5.2
Loneliness (linear analysis)	128	-7.3
Loneliness (MTAG)	170	-5.5
Loneliness (multivariate analysis)	193	-6.1
Longevity	226	-3.6
Longevity (85 years and older)	2	-1.8
Longevity (90 years and older)	58	-3.3
Longitudinal alcohol consumption	33	-3.3
Longitudinal change in brain amyloid plaque burden	39	-4.1
Long-term memory (delayed word recall task)	3	-3.1
Low density lipoprotein cholesterol levels	458	-8.6
Lower body strength	27	-3.2
Lower facial height	46	-3.2
Low-grade serous and serous borderline ovarian cancer	20	-4.5
Low-grade serous ovarian cancer	1	-2.2
Low high density lipoprotein cholesterol levels	79	-4.0
Low tan response	121	-5.3
Low vWF levels	19	-3.8
Low white blood cell count (conditioned on rs2814778)	22	-3.8
Lp (a) levels	31	-2.7
Lumbar spine bone mineral density	306	-5.1
Lumbar spine bone mineral density (integral)	105	-4.7
Lumbar spine bone mineral density (trabecular)	57	-4.1
Lung adenocarcinoma	257	-11.5
Lung cancer	482	-6.3
Lung cancer (asbestos exposure interaction)	1	-2.8
Lung Cancer (DNA repair capacity)	3	-2.7
Lung cancer in ever smokers	246	-5.2
Lung cancer in never smokers	122	-4.8
Lung cancer (smoking interaction)	24	-5.9
Lung cancer x radon exposure interaction (1df)	41	-5.0
Lung disease severity in cystic fibrosis	52	-5.3
Lung function (FEV1)	361	-5.2
Lung function (FEV1/FVC)	4139	-14.4
Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction)	2	-2.1
Lung function (FEV1) in asthma (dust mite allergen exposure interaction)	60	-1.9
Lung function (forced expiratory flow during mid-portion (25 and 75) of forced vital capacity)	17	-4.4
Lung function (forced expiratory volume in 1 second)	26	-2.8
Lung function (forced vital capacity)	19	-2.0
Lung function (FVC)	3769	-7.2
Lung function (maximal voluntary ventilation)	7	-2.8
Lupus nephritis in systemic lupus erythematosus	77	-3.7
Luteinizing hormone levels in polycystic ovary syndrome	11	-2.4
Lymphocyte counts	524	-12.2
Lymphocyte percentage of white cells	340	-6.4
Lymphoma	24	-4.7
Macrophage colony stimulating factor levels	128	-5.8
Macrophage inflammatory protein 1a levels	67	-2.9
Macrophage inflammatory protein 1b levels	111	-4.3
Macrophage Migration Inhibitory Factor levels	41	-4.8
Macular telangiectasia type 2	3	-3.4
Macular thickness	577	-6.1
Magnesium levels	116	-4.3
Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)	5	-1.9
Major coronary event in darapladib-treated cardiovascular disease (time to event)	3	-2.1
Major depression and alcohol dependence	318	-5.6
Major depressive disorder	1148	-4.8
Major depressive disorder (broad)	82	-3.2
Major depressive disorder (ICD-10 coded)	4	-2.9
Major depressive disorder (probable)	56	-5.6
Major depressive disorder (stressful life events interaction)	21	-2.1
Major depressive disorder (unexposed to adversity)	16	-2.7
Malaria	63	-3.0
Male fertility	31	-2.7
Male infertility	36	-4.0
Male-pattern baldness	4028	-11.6
Male sexual orientation	11	-4.1
Mammographic density	26	-3.2
Mammographic density (dense area)	72	-2.3
Mammographic density (non-dense area)	33	-4.1
Marginal zone lymphoma	2	-2.4
Maternal history of Alzheimer's disease	7	-3.5
Mathematical ability	53	-5.7
Matrix metalloproteinase levels	53	-4.3
Maximal oxygen uptake response	12	-2.4
Maximum cranial length	29	-2.6
Maximum cranial width	36	-5.1
Mean arterial pressure	608	-4.8
Mean arterial pressure (alcohol consumption interaction)	23	-5.2
Mean arterial pressure x alcohol consumption interaction (2df test)	325	-6.7
Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)	143	-8.2
Mean corpuscular hemoglobin	2132	-49.2
Mean corpuscular hemoglobin concentration	264	-18.3
Mean corpuscular volume	762	-44.2
Mean diameter of HDL particles	12	-6.2
Mean forced vital capacity from 2 exams	15	-4.1
Mean platelet volume	825	-18.4
Measles	102	-3.5
Meconium ileus in cystic fibrosis	25	-4.1
Medication adherence in chronic diseases	24	-2.5
Medium HDL particle concentration	12	-6.2
Medium LDL particle concentration	5	-2.9
Melanoma	122	-5.5
Memory dysfunction in frontotemporal lobe dementia	1	0.0
Memory performance	5	-7.3
Menarche (age at onset)	2189	-4.3
Menarche and menopause (age at onset)	15	-2.4
Meningococcal disease	1	0.0
Menopause (age at onset)	174	-3.5
Menstruation quality of life impact (acne)	4	-2.2
Menstruation quality of life impact (aggressiveness)	53	-3.5
Menstruation quality of life impact (bowel movement)	25	-3.8
Menstruation quality of life impact (depression)	22	-3.4
Menstruation quality of life impact (dysmenorrhea)	42	-3.3
Menstruation quality of life impact (edema)	4	-8.3
Menstruation quality of life impact (fever)	21	-6.8
Menstruation quality of life impact (headache)	14	-4.1
Menstruation quality of life impact (increased appetite)	10	-3.6
Menstruation quality of life impact (joint pain)	2	-2.7
Menstruation quality of life impact (loss of concentration)	103	-3.1
Menstruation quality of life impact (nervousness)	24	-3.8
Menstruation quality of life impact (pressure in breast)	11	-2.1
Menstruation quality of life impact (sleepiness)	5	-1.8
Menstruation quality of life impact (stiff neck)	35	-2.3
Mental composite score	24	-4.9
Mental development (prenatal lead exposure interaction)	4	-1.9
Metabolic coherence (transcriptomic)	10	-3.8
Metabolic syndrome	158	-4.1
Metabolic syndrome (bivariate traits)	43	-3.8
Metabolic syndrome (multivariate analysis)	34	-3.3
Metabolic traits	85	-3.7
Metabolite levels	205	-3.5
Metabolite levels (5-HIAA/ MHPG Ratio)	12	-4.9
Metabolite levels (5-HIAA)	60	-9.1
Metabolite levels (Dihydroxy docosatrienoic acid)	124	-4.3
Metabolite levels (HVA-5-HIAA Factor score)	37	-3.0
Metabolite levels (HVA/5-HIAA ratio)	71	-4.3
Metabolite levels (HVA/MHPG ratio)	83	-3.0
Metabolite levels (HVA)	15	-3.3
Metabolite levels (lipid measures)	1	-1.9
Metabolite levels (lipoprotein measures)	101	-6.6
Metabolite levels (MHPG)	68	-3.3
Metabolite levels (Pyroglutamine)	104	-2.6
Metabolite levels (small molecules and protein measures)	19	-2.9
Metabolite levels (X-11787)	206	-2.6
Metastasis at diagnosis in osteosarcoma	6	-2.8
Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event)	123	-4.4
Methadone dose in opioid dependence	184	-2.8
Methotrexate-induced interstitial lung disease in rheumatoid arthritis	23	-3.6
Methotrexate phramacokinetics (acute lymphoblastic leukemia)	53	-6.9
Microalbuminuria	49	-3.9
Middle childhood and early adolescence aggressive behavior	38	-3.4
middle facial morphology traits (quantitative measurement)	11	-4.5
Midgestational circulating levels of organochlorine pesticides	1	-2.7
Midgestational circulating levels of PBDEs	6	-1.3
Midgestational circulating levels of PBDEs (fetal genetic effect)	26	-3.4
Midgestational circulating levels of PCBs	153	-3.8
Midgestational circulating levels of PCBs (fetal genetic effect)	9	-4.1
Midgestational cytokine/chemokine levels (fetal genetic effect)	4	-2.4
Midgestational cytokine/chemokine levels (maternal genetic effect)	25	-2.5
Migraine	689	-2.6
Migraine - clinic-based	214	-4.3
Migraine with aura	136	-8.6
Migraine without aura	247	-3.4
Mild influenza (H1N1) infection	89	-4.2
Milk allergy	14	-2.0
Mitochondrial DNA copy number	17	-1.9
Mitochondrial DNA copy number (white blood cells)	4	-2.6
Mitochondrial DNA levels	101	-3.1
Mitral valve prolapse	108	-3.8
Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection	12	-6.0
Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)	10	-3.4
Moderate to vigorous physical activity levels	125	-10.4
Modic changes	41	-2.7
Modified Stumvoll Insulin Sensitivity Index (BMI interaction)	48	-2.3
Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI)	4	-2.7
Molar-incisor hypomineralization	29	-5.1
Monobrow	202	-3.5
Monobrow thickness	30	-3.8
Monocyte chemoattractant protein-1 levels	77	-4.1
Monocyte chemoattractant protein-3 levels	33	-3.0
Monocyte count	636	-28.7
Monocyte early outgrowth colony forming units	2	-2.2
Monocyte-lymphocyte ratio	7	-5.6
Monocyte percentage of white cells	634	-25.3
Monokine induced by gamma interferon levels	100	-4.0
Mononucleosis	80	-5.1
Mood disorder and prion disease	23	-4.3
Mood disorder in prion disease	16	-2.9
Mood instability	329	-5.2
Morbidity-free survival	51	-3.4
Morning person	2156	-22.4
Morning vs. evening chronotype	510	-14.0
Mortality in heart failure	73	-3.2
Mortality in sepsis	31	-4.4
Mosquito bite size	468	-7.5
Motion sickness	208	-3.2
Motor composite score	52	-4.5
Mouth morphology (principal component model)	1	-1.4
Moyamoya disease	178	-5.5
Mucinous adenocarcinoma in colorectal cancer	35	-3.8
Mucinous ovarian carcinoma	5	-3.0
Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	8	-3.9
Multiple keratinocyte cancers	73	-41.4
Multiple myeloma	122	-4.6
Multiple myeloma and monoclonal gammopathy	14	-3.2
Multiple myeloma (hyperdiploidy)	33	-2.9
Multiple myeloma (IgH translocation)	107	-5.2
Multiple sclerosis	1001	-25.7
Multiple sclerosis (age of onset)	50	-2.9
Multiple sclerosis and C-reactive protein levels (pleiotropy)	5	-2.8
Multiple sclerosis and HDL levels (pleiotropy)	23	-3.3
Multiple sclerosis and LDL levels (pleiotropy)	12	-2.7
Multiple sclerosis and systolic blood pressure (pleiotropy)	10	-6.3
Multiple sclerosis and triglyceride levels (pleiotropy)	32	-10.2
Multiple sclerosis and type 2 diabetes (pleiotropy)	5	-3.1
Multiple sclerosis--Brain Glutamate Levels	18	-3.4
Multiple sclerosis (OCB status)	28	-10.0
Multiple sclerosis (severity)	103	-5.9
Multiple system atrophy	60	-2.5
Multiple system atrophy (pathologically confirmed)	4	-4.2
Mumps	98	-5.4
Musician's dystonia	2	-2.5
Myasthenia gravis	35	-5.4
Myeloid white cell count	413	-12.8
Myeloproliferative neoplasms	13	-3.2
Myocardial infarction	135	-4.6
Myocardial infarction (early onset)	45	-3.8
Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction)	8	-2.9
Myocardial infarction in darapladib-treated cardiovascular disease (time to event)	11	-2.7
Myocardial infarction in hypertension (calcium channel blocker interaction)	5	-3.9
Myopia	137	-3.8
Myopia (age of diagnosis)	298	-5.5
Myopia (pathological)	604	-11.8
Myopia (severe)	22	-2.4
Myringotomy	58	-4.4
Narcolepsy	42	-5.7
Narcolepsy (age of onset)	1	-2.6
Narcolepsy (onset before 2009 H1N1 influenza pandemic)	4	-7.0
Narcolepsy with cataplexy	40	-5.7
Narrowest width of the femoral neck	5	-4.9
Nasal polyps	32	-3.4
Nasopharyngeal carcinoma	34	-4.1
Natriuretic peptide levels	3	-2.0
Negative urgency	7	-4.0
Neonatal cytokine/chemokine levels (fetal genetic effect)	38	-4.4
Neonatal cytokine/chemokine levels (maternal genetic effect)	17	-3.6
Neonatal lupus	51	-2.3
Nephrolithiasis	2	-3.0
Nephropathy	18	-7.5
Nephrotic syndrome (acquired)	28	-2.7
Neuranatomic and neurocognitive phenotypes	30	-3.6
Neuritic plaques or cerebral amyloid angiopathy (pleiotropy)	2	-2.1
Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)	2	-2.1
Neuritic plaques or neurofibrillary tangles (pleiotropy)	7	-2.8
Neuritic plaque	18	-3.8
Neuroblastoma	5	-2.1
Neurociticism	639	-3.6
Neurocognitive impairment in HIV-1 infection (continuous)	68	-5.2
Neurocognitive impairment in HIV-1 infection (dichotomous)	12	-2.4
Neurofibrillary tangles	46	-2.6
Neuromyelitis optica	2	-2.4
Neuromyelitis optica (AQP4-IgG-positive)	2	-2.4
Neuropathic pain in head and neck cancer	6	-4.3
Neuropathic pain in type 2 diabetes	65	-2.2
Neuroticism	3620	-5.9
Neuroticism (age interaction)	34	-3.7
Neuroticism (MTAG)	300	-2.9
Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)	1	-1.7
Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)	1	-1.7
Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)	1	-1.7
Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)	12	-6.0
Neutrophil count	527	-10.0
Neutrophil level response to clozapine in treatment-resistant schizophrenia	1	-1.8
Neutrophil percentage of granulocytes	426	-17.0
Neutrophil percentage of white cells	296	-12.7
Nevirapine-induced rash	5	-5.5
Nevus count	27	-3.3
Nevus count or cutaneous melanoma	77	-5.7
N-glycan levels	136	-8.7
Nicotine dependence	87	-6.4
Nicotine dependence and major depression (severity of comorbidity)	199	-2.6
Nicotine dependence symptom count	100	-6.2
nicotine metabolite ratio in current smokers	16	-5.7
Nicotine use	8	-1.5
Nicotine withdrawal	28	-3.0
Nicotine withdrawal symptom count	39	-4.6
Night sleep phenotypes	617	-5.3
Nodular sclerosis Hodgkin lymphoma	59	-10.3
Non-albumin protein levels	180	-7.4
Nonalcoholic fatty liver disease	65	-6.5
Non-alcoholic fatty liver disease histology (AST)	47	-2.8
Non-alcoholic fatty liver disease histology (lobular)	46	-3.9
Non-alcoholic fatty liver disease histology (other)	87	-4.6
Nonalcoholic steatohepatitis-derived hepatocellular carcinoma	1	-2.5
Non-cardia gastric cancer	57	-4.6
Non-glioblastoma glioma	38	-6.1
Non-melanoma skin cancer	320	-6.1
Non-obstructive azoospermia	48	-18.9
Non-response to antidepressants and depression	2	-3.1
Non-response to bupropion and depression	51	-5.3
Non-response to citalopram or escitalopram and depression	4	-2.2
Non-response to selective serotonin reuptake inhibitors and depression	2	-2.9
Non-Richardson's syndrome vs Richardson's syndrome in progressive supranuclear palsy	2	-2.5
Non-small cell lung cancer	45	-3.0
Non-small cell lung cancer (survival)	28	-3.1
Non-substance related behavioral disinhibition	57	-4.4
Nonsyndromic cleft lip with cleft palate	218	-6.9
Nonsyndromic cleft lip with or without cleft palate	59	-14.3
Nonsyndromic cleft lip with or without cleft palate x sex interaction (2df test)	40	-3.4
Nontyphoidal Salmonella bacteraemia	2	-2.4
Non-word reading	154	-3.9
Non-word repetition	13	-2.4
Normal body mass index vs. thin	2	-2.3
Normal facial asymmetry (angle of deformation score)	3	-1.6
Normal facial asymmetry (angle of surface orientation score)	7	-2.6
Normal facial asymmetry (deformation magnitude)	5	-4.4
Normalized brain volume	3	-6.7
Nose length	2	-1.0
Nose morphology	264	-6.2
Nose size	167	-7.4
N-terminal pro B-type natriuretic peptide levels	6	-3.7
Nucleus accumbens volume in trauma-exposed individuals	13	-3.9
Number of children	34	-2.4
Number of children (6+ vs. 0 or 1)	64	-2.5
Number of children ever born	25	-3.4
Number of common colds	54	-3.9
Number of pregnancies	88	-2.4
Number of sexual partners	734	-4.5
Number of stillbirths in continuous marriage	4	-3.8
Number of twin births	7	-3.1
Obese vs. thin	57	-4.1
Obesity	368	-3.6
Obesity (early onset extreme)	166	-4.7
Obesity (extreme)	235	-4.0
Obesity in adult survivors of childhood cancer exposed to cranial radiation	7	-1.7
Obesity-related traits	3295	-3.5
Obesity without metabolic disease	130	-4.6
Objective response to lithium treatment	1	-1.9
Objective response to lithium treatment in bipolar disorder	3	-1.6
Obsessive-compulsive disorder	160	-2.9
Obsessive-compulsive disorder or autism spectrum disorder	51	-3.8
Obsessive-compulsive disorder x sex interaction	6	-6.1
Obsessive-compulsive symptoms	61	-3.4
Obstetric antiphospholipid syndrome	23	-3.4
Obstructive sleep apnea	23	-2.4
Obstructive sleep apnea (average oxygen saturation during sleep)	4	-2.8
Obstructive sleep apnea during REM sleep (apnea hypopnea index)	8	-4.1
Obstructive sleep apnea trait (apnea hypopnea index)	112	-5.3
Obstructive sleep apnea trait (average respiratory event duration)	36	-3.7
Offspring birth weight	422	-5.6
Oleic acid (18:1n-9) levels	12	-2.7
Oligoclonal band status in multiple sclerosis	5	-6.1
Open-angle glaucoma and optic cup area	3	-2.3
Open-angle glaucoma and vertical cup-disc ratio	27	-6.7
Opioid dependence	23	-3.8
Opioid requirements during laparoscopic-assisted colectomy	2	-1.6
Opioid sensitivity	14	-4.9
Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder	48	-3.5
Optic cup area	243	-5.2
Optic disc area	188	-5.7
Optic disc parameters	19	-3.1
Optic nerve measurement (cup area)	100	-4.5
Optic nerve measurement (cup-to-disc ratio)	90	-4.5
Optic nerve measurement (disc area)	21	-4.9
Optic nerve measurement (rim area)	38	-2.3
Oral cavity and pharyngeal cancer	3	-3.2
Oral cavity cancer	8	-2.2
Orofacial clefts	170	-4.4
Orofacial clefts (maternal alcohol consumption interaction)	2	-3.9
Oropharynx cancer	62	-2.4
Orthostatic hypotension	90	-3.4
Ossification of the posterior longitudinal ligament of the spine	80	-5.1
Osteoarthritis	145	-4.3
Osteoarthritis biomarkers	13	-2.4
Osteoarthritis (hip)	88	-6.5
Osteoarthritis (hospital diagnosed)	3	-2.0
Osteoarthritis of the hip (hospital diagnosed)	36	-3.5
Osteoarthritis of the hip or knee	112	-4.5
Osteoarthritis of the hip or knee (hospital diagnosed)	6	-2.4
Osteoarthritis of the hip (with total joint replacement)	15	-3.4
Osteoarthritis of the knee (hospital diagnosed)	8	-2.1
Osteoarthritis of the knee (with total joint replacement)	18	-5.6
Osteoarthritis (self-reported)	75	-2.9
Osteolysis in total hip arthroplasty	23	-5.6
Osteolysis in total hip arthroplasty (time to prosthesis revision)	25	-2.1
Osteoporosis	14	-3.8
Osteoporosis-related phenotypes	11	-5.9
Osteoprotegerin levels	34	-3.3
Osteosarcoma	6	-3.3
Other erythrocyte phenotypes	10	-5.5
Otitis media	2	-4.4
Otitis media (chronic)	1	-2.3
Otitis media (chronic/recurrent)	11	-3.6
Otitis media (recurrent)	2	-2.7
Otosclerosis	10	-1.7
Ovarian cancer	105	-5.2
Ovarian cancer in BRCA1 mutation carriers	15	-6.8
Ovarian cancer in BRCA2 mutation carriers	5	-4.4
Ovarian disease with few adhesions	12	-2.9
Ovarian reserve	65	-5.5
Overall survival in osteosarcoma	62	-2.4
Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin	52	-3.1
Overweight status	28	-5.6
Paclitaxel disposition in epithelial ovarian cancer	157	-3.7
Paclitaxel-induced cytotoxicity	34	-3.7
Paclitaxel-induced neuropathy	52	-4.4
Paget's disease	26	-5.6
Pain	28	-3.5
Pain medicine use during menstruation	26	-5.1
Pallidum volume in trauma-exposed individuals	4	-1.4
Palmitic acid (16:0) levels	82	-3.5
Palmitoleic acid (16:1n-7) levels	57	-2.7
Pancreatic cancer	207	-4.8
Pancreatic ductal adenocarcinoma	24	-4.9
Pancreatitis	23	-4.1
Paneth cell defects in Crohn's disease	37	-3.9
Panic disorder	83	-3.9
Papillary thyroid cancer	45	-4.3
Parasitemia in Tripanosoma cruzi seropositivity	123	-2.6
Parental extreme longevity (95 years and older)	163	-4.3
Parental lifespan	18	-4.9
Parental longevity (at least one long-lived parent)	6	-3.7
Parental longevity (both parents in top 10)	11	-4.5
Parental longevity (combined parental age at death)	110	-4.5
Parental longevity (combined parental attained age, Martingale residuals)	112	-4.6
Parental longevity (father's attained age)	25	-3.4
Parental longevity (mother's age at death)	111	-3.5
Parent of origin effect on language impairment (paternal)	22	-3.2
Parkinson disease and lewy body pathology	65	-9.8
Parkinsonism in frontotemporal lobe dementia	11	-3.4
Parkinson's disease	432	-4.9
Parkinson's disease (age of onset)	7	-2.9
Parkinson's disease (familial, age at onset)	6	-4.1
Parkinson's disease (motor and cognition)	14	-6.7
Parkinson's disease (pesticide exposure interaction)	1	-1.4
Partial epilepsies	23	-2.8
Paternal history of Alzheimer's disease	7	-3.5
Pathological gambling	5	-6.4
PCA3 expression level	11	-3.4
Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma	4	-3.6
Peak creatinine levels in vancomycin therapy	6	-2.4
Peak expiratory flow	721	-8.3
Peak insulin response	102	-4.5
Peak velocity of the mitral A-wave	4	-5.0
Peanut allergy	33	-4.4
Peanut allergy (maternal genetic effects)	1	-4.4
Peanut allergy (parent-of-origin effect)	10	-5.2
Pediatric areal bone mineral density (concordant skeletal phenotype)	1	-3.9
Pediatric areal bone mineral density (radius)	85	-4.6
Pediatric areal bone mineral density (radius vs spine & hip discordant skeletal phenotype)	28	-5.2
Pediatric autoimmune diseases	81	-6.0
Pediatric bone mineral content (femoral neck)	48	-4.3
Pediatric bone mineral content (hip)	83	-4.3
Pediatric bone mineral content (radius)	66	-7.0
Pediatric bone mineral content (spine)	72	-3.2
Pediatric bone mineral density (femoral neck)	42	-4.1
Pediatric bone mineral density (hip)	46	-3.2
Pediatric bone mineral density (spine)	63	-4.8
Pediatric non-alcoholic fatty liver disease activity score	30	-2.1
Pediatric nonalcoholic steatohepatitis	2	-2.1
PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia	8	-2.6
Pelvic organ prolapse	73	-4.0
Pelvic organ prolapse (moderate/severe)	96	-4.4
Pemphigus foliaceus	7	-3.5
Pemphigus vulgaris	24	-2.7
Perceived unattractiveness to mosquitoes	155	-5.6
Percentage gas trapping	97	-5.3
Percent glycated albumin	2	-1.7
Percent mammographic density	37	-8.0
Perceptual rivalry (voluntary modulation strength)	3	-4.8
Pericardial adipose tissue adjusted for height and weight	45	-2.7
Pericardial fat	42	-2.8
Periodontal microbiota	60	-3.5
Periodontitis	75	-4.7
Periodontitis (CDC/AAP)	43	-3.0
Periodontitis (DPAL)	74	-3.3
Periodontitis (Mean PAL)	79	-3.5
Periodontitis (PAL4Q3)	47	-3.0
Peripheral arterial disease (traffic-related air pollution interaction)	619	-3.0
Peripheral artery disease	81	-2.5
Permanent tooth development	6	-2.7
Personality dimensions	71	-3.9
Personality traits in bipolar disorder	14	-3.1
Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)	16	-3.0
Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	18	-6.4
Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)	11	-2.3
Philtrum width	86	-7.4
Phoneme awareness	82	-4.1
Phospholipid levels in large HDL	14	-5.8
Phospholipid levels in medium HDL	14	-5.8
Phospholipid levels (plasma)	27	-4.4
Phosphorus levels	41	-4.5
Photic sneeze reflex	444	-4.5
Physical activity (moderate intensity activity duration)	23	-4.2
Physical activity (overall physical activity time)	121	-8.2
Phytosterol levels	2	-4.3
Pit-and-Fissure caries	72	-2.7
Placebo response in major depressive disorder ( change in symptom score)	45	-3.1
Placental abruption	17	-2.3
Plantar warts	82	-4.3
Plasma amyloid beta peptide concentrations (ABx-40)	32	-5.6
Plasma amyloid beta peptide concentrations (ABx-42)	38	-3.4
Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer	37	-7.3
Plasma androstenedione levels in resected early stage-receptor positive breast cancer	3	-3.7
Plasma clozapine levels in treatment-resistant schizophrenia	1	-2.7
Plasma clozapine-norclozapine ratio in treatment-resistant schizophrenia	1	0.0
Plasma clusterin levels	178	-3.1
Plasma cystastin c levels in acute coronary syndrome	12	-4.4
Plasma factor VII activating protease levels	165	-60.7
Plasma free amino acid levels	81	-3.7
Plasma free amino acid levels (adjusted for one other PFAA)	16	-2.5
Plasma free amino acid levels (adjusted for twenty other PFAAs)	58	-4.0
Plasma homocysteine levels	11	-3.1
Plasma homocysteine levels (post-methionine load test)	3	-2.8
Plasma kynurenine levels in major depressive disorder	8	-1.9
Plasma kynurenine to tryptophan ratio in major depressive disorder	6	-1.2
Plasma neurofilament light levels	8	-2.2
Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)	36	-5.6
Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)	38	-4.0
Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	86	-2.9
Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid)	24	-13.9
Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid)	4	-4.0
Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	107	-3.5
Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	67	-3.9
Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)	92	-4.5
Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)	40	-3.0
Plasma parathyroid hormone levels	86	-2.7
Plasma plasminogen levels	5	-4.1
Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease	45	-3.5
Plasma pyridoxic acid to pyridoxal phosphate ratio	5	-5.6
Plasma renin activity levels	39	-7.6
Plasma thyroid-stimulating hormone levels	113	-2.7
Plasma trimethylamine N-oxide levels	12	-2.9
Plasma trimethyllysine levels	22	-5.0
Plasma t-tau levels	17	-2.7
Plasminogen activator inhibitor type 1 levels (PAI-1)	7	-5.5
Platelet aggregation	50	-5.6
Platelet count	829	-13.5
Plateletcrit	638	-16.1
Platelet-derived growth factor BB levels	175	-3.8
Platelet distribution width	465	-17.6
Platelet thrombus formation	19	-9.1
Platinum-induced myelosuppression in non-small cell lung cancer	10	-2.5
Pneumococcal bacteremia	21	-6.4
Pneumoconiosis in silica exposure	4	-2.5
Pneumonia	156	-4.3
Political ideology	58	-8.2
Polychlorinated biphenyl levels	141	-4.8
Polycystic ovary syndrome	170	-3.9
Polymyositis	13	-4.3
Poor prognosis in Crohn's disease	3	-2.8
Positive affect	1113	-6.6
Positive urgency	82	-4.3
Possible neuropathic pain in post total joint replacement surgery for osteoarthritis	42	-5.4
Post bronchodilator FEV1	828	-6.2
Post bronchodilator FEV1/FVC ratio	1157	-3.2
Post bronchodilator FEV1/FVC ratio in COPD	326	-3.1
Post bronchodilator FEV1/FVC ratio in smoking	6	-2.8
Post bronchodilator FEV1 in COPD	200	-4.1
Post bronchodilator percent predicted FEV1 in smoking	21	-6.8
Postburn hypertrophic scarring severity	3	0.0
Postburn scar height	1	0.0
Postburn scar pliability	47	-4.3
Posterior cortical atrophy and Alzheimer's disease	95	-3.4
Postoperative atrial fibrillation in coronary artery bypass grafting surgery	2	0.0
Postoperative survival time in hepatocellular carcinoma	27	-4.1
Postprandial triglyceride response to high fat diet meal	21	-3.5
Post-traumatic stress disorder	164	-4.5
Post-traumatic stress disorder (asjusted for relatedness)	32	-3.2
Potassium levels	26	-5.5
Pre bronchodilator FEV1/FVC ratio	39	-3.3
Pre bronchodilator FEV1/FVC ratio in never-smokers	41	-3.7
Preeclampsia	53	-5.4
Premature menopause in childhood cancer survivors	39	-4.1
Premature ovarian failure	9	-2.8
Preschool internalizing problems	32	-3.3
Presence of antiphospholipid antibodies	143	-3.2
Preterm birth (maternal effect)	29	-4.0
Pre-treatment pain in head and neck squamous cell carcinoma	35	-3.5
Prevalent atrial fibrillation	70	-5.6
Prevalent type 2 diabetes	50	-4.8
Primary biliary cholangitis	207	-11.4
Primary biliary cirrhosis	70	-9.7
Primary sclerosing cholangitis	125	-7.9
Primary tooth development (number of teeth)	38	-3.6
Primary tooth development (time to first tooth eruption)	27	-6.6
Primary vesicoureteric reflux	4	-3.5
PR interval	232	-4.9
PR interval in Tripanosoma cruzi seropositivity	288	-2.6
Prion diseases	116	-4.3
Problematic alcohol use in trauma-exposed individuals	14	-4.4
Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)	9	-3.4
Progression free survival in metastatic colorectal cancer (chemotherapy interaction)	1	-2.1
Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel	1	-1.8
Progressive supranuclear palsy	19	-3.9
Proinsulin levels	71	-2.7
Proliferative diabetic retinopathy in type 2 diabetes	3	-4.5
Proliferative diabetic retinopathy (vs no DR)	100	-4.8
Proliferative diabetic retinopathy (vs NPDR and no DR)	92	-4.3
Prostate cancer	668	-7.4
Prostate cancer (advanced)	91	-9.1
Prostate cancer aggressiveness	3	-3.4
Prostate cancer (early onset)	64	-7.0
Prostate cancer (survival)	14	-3.6
Prostate-specific antigen levels	120	-5.7
Prostate-specific antigen levels (conditioned on lead SNPs)	51	-5.1
Protein C levels	5	-1.5
Protein quantitative trait loci	113	-3.4
Proteinuria and chronic kidney disease	7	-2.6
Proteinuria in chronic kidney disease	6	-2.4
Prothrombin fragments F1+2 levels in ischemic stroke	9	-4.8
Prothrombin time	41	-3.2
PR segment	21	-3.8
Prudent dietary pattern	89	-3.3
Psoriasis	398	-9.0
Psoriasis vulgaris	191	-4.4
Psoriatic arthritis	23	-3.7
Psychiatric diseases (pleiotropy) (HIPO component 1)	9	-3.0
Psychological distress	41	-2.5
Psychosis and Alzheimer's disease	84	-3.6
Psychosis (atypical)	27	-6.2
Psychosis in Alzheimer's disease	45	-5.5
Psychosis proneness (hypomanic personality scale)	6	-2.4
Psychosis proneness (hypomanic personality scale and perceptual aberration scale)	3	-2.7
Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale)	11	-2.8
Psychosis proneness (hypomanic personality scale and revised social anhedonia scale)	21	-3.8
Psychosis proneness (perceptual aberration scale and revised social anhedonia scale)	10	-2.8
Psychosis proneness (revised physical anhedonia scale)	3	-2.1
Psychosis proneness (revised physical anhedonia scale and revised social anhedonia scale)	9	-2.8
Psychosis proneness (revised social anhedonia scale)	9	-2.8
Psychotic symptoms in prion disease	26	-4.0
Pubertal anthropometrics	136	-5.1
Pulmonary arterial hypertension	7	-2.8
Pulmonary arterial hypertension (without BMPR2 mutations)	1	-1.9
Pulmonary emphysema	4	-1.5
Pulmonary function	213	-4.8
Pulmonary function decline	91	-3.8
Pulmonary function in asthmatics	40	-5.2
Pulmonary function (smoking interaction)	205	-3.2
Pulse pressure	2667	-11.5
Pulse pressure (alcohol consumption interaction)	7	-2.3
Pulse pressure in young-onset hypertension	16	-3.6
Pulse pressure x alcohol consumption interaction (2df test)	158	-6.1
Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)	20	-4.6
Pursuit maintenance gain	306	-2.8
Pursuit maintenance gain in psychotic disorders	17	-2.5
Putamen volume	70	-3.3
P wave duration	43	-5.0
P wave terminal force	35	-4.7
Pyoderma gangrenosum in inflammatory bowel disease	13	-2.8
QRS complex (12-leadsum)	116	-5.3
QRS complex (Cornell)	105	-3.8
QRS complex (Sokolow-Lyon)	55	-3.5
QRS duration	430	-3.7
QRS duration in Tripanosoma cruzi seropositivity	83	-3.4
QRS interval (sulfonylurea treatment interaction)	108	-3.8
QT interval	693	-5.5
QT interval (ambient particulate matter interaction)	87	-5.2
QT interval (drug interaction)	62	-3.7
QT interval in Tripanosoma cruzi seropositivity	53	-3.3
QT interval (sulfonylurea treatment interaction)	57	-2.4
Quantitative traits	144	-3.7
Radiation response	24	-3.0
RANTES levels	101	-4.0
Rapid automised naming of digits	89	-4.0
Rapid automised naming of letters	152	-4.4
Rapid automised naming of pictures	66	-2.7
Rate of cognitive decline in mild cognitive impairment (time interaction)	1	-2.9
Reaction time	2133	-23.9
Reading ability (multivariate)	123	-3.4
Reading and spelling	39	-2.4
Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy)	10	-4.8
Reading disability or specific language impairment (pleiotropy)	79	-3.9
Reasoning	3	-3.0
Recalcitrant atopic dermatitis	65	-6.7
Recombination measurement	10	-1.4
Recurrent major depressive disorder	82	-3.4
Red blood cell count	3165	-17.6
Red blood cell density in sickle cell anemia	29	-3.7
Red blood cell fatty acid levels	1	-1.9
Red blood cell traits	164	-10.3
Red cell distribution width	1588	-45.5
Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A	2	-1.6
Red vs. brown/black hair color	87	-7.0
Red wine liking	12	-4.0
Reflection (response to stress)	45	-3.7
Refractive astigmatism	257	-4.7
Refractive error	116	-4.8
Refractory celiac disease type II	6	-2.7
Regular attendance at a gym or sports club	14	-2.2
Regular attendance at a pub or social club	92	-2.8
Regular attendance at a religious group	96	-2.7
Relapse in multiple sclerosis	3	-1.9
Relative amplitude of rest-activity cycles	20	-2.5
Relative hand skill	26	-6.4
Relative hand skill in reading disability	30	-4.6
Relative wall thickness	13	-5.6
Remission after SSRI treatment in major depression	5	-2.9
Remission after SSRI treatment in MDD or neuroticism	11	-2.9
Remission after SSRI treatment in MDD or openness	2	-3.1
Renal cell carcinoma	123	-6.6
Renal function and chronic kidney disease	24	-4.3
Renal function-related traits (BUN)	67	-4.2
Renal function-related traits (eGRFcrea)	85	-5.2
Renal function-related traits (sCR)	47	-3.1
Renal function-related traits (urea)	8	-3.0
Renal sinus fat	22	-2.2
Renal transplant outcome	7	-3.0
Residual cognition	41	-4.8
Resistance to antihypertensive treatment in hypertension	105	-5.9
Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous)	3	-3.6
Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous)	18	-3.9
Resistant hypertension	13	-7.2
Resistin levels	18	-2.8
Respiratory diseases	406	-9.8
Response to abacavir-containing treatment in HIV-1 infection (virologic failure)	68	-4.5
Response to acetaminophen (hepatotoxicity)	35	-13.6
Response to alcohol consumption (flushing response)	5	-3.0
Response to amphetamines	347	-3.2
Response to angiotensin II receptor blocker therapy	104	-3.6
Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)	16	-4.8
Response to antidepressants	53	-4.1
Response to antidepressants and depression	2	-2.6
Response to antidepressants in depression	7	-2.9
Response to antidepressants (symptom improvement)	153	-2.7
Response to antidepressants (symptom remission)	35	-2.9
Response to antidepressant treatment (citalopram)	23	-7.0
Response to anti-depressant treatment in major depressive disorder	52	-4.4
Response to antineoplastic agents	48	-5.4
Response to antipsychotic therapy (extrapyramidal side effects)	105	-2.2
Response to antipsychotic treatment	389	-3.5
Response to antipsychotic treatment in schizophrenia	35	-4.8
Response to antipsychotic treatment in schizophrenia (reasoning)	36	-3.5
Response to antipsychotic treatment in schizophrenia (working memory)	48	-2.6
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)	33	-3.7
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)	94	-2.6
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)	32	-4.1
Response to anti-TNF alpha therapy in inflammatory bowel disease	8	-2.3
Response to anti-TNF therapy in rheumatoid arthritis	22	-4.0
Response to aripiprazole in schizophrenia	14	-3.9
Response to bleomycin (chromatid breaks)	4	-5.1
Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)	65	-4.4
Response to bupropion and depression	9	-3.4
Response to bupropion in depression	12	-3.6
Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50)	20	-5.2
Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50)	4	-5.0
Response to carboplatin in ovarian cancer (MTT IC50)	66	-3.0
Response to chemotherapy in breast cancer (hypertension) (bevacizumab)	12	-3.3
Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)	38	-2.8
Response to cholinesterase inhibitors in Alzheimer's disease	15	-3.2
Response to citalopram or escitalopram and depression	1	-2.2
Response to citalopram or escitalopram in depression	15	-2.9
Response to citalopram treatment	70	-4.2
Response to cognitive-behavioural therapy in anxiety disorder	123	-4.1
Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis	29	-3.2
Response to cytadine analogues (cytosine arabinoside)	44	-3.7
Response to cytidine analogues (gemcitabine)	22	-4.7
Response to Dalcetrapib treatment in acute coronary syndrome	4	-3.0
Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)	194	-5.0
Response to exercise (triglyceride level interaction)	20	-3.3
Response to fenofibrate	10	-5.2
Response to fenofibrate (adiponectin levels)	39	-4.2
Response to fenofibrate (HDL cholesterol levels)	5	-2.1
Response to fenofibrate (total cholesterol levels)	2	-2.5
Response to fenofibrate (triglyceride levels)	12	-2.8
Response to gemcitabine in pancreatic cancer	12	-1.8
Response to haloperidol in schizophrenia	32	-2.3
Response to hepatitis B vaccine	40	-4.5
Response to hepatitis C treatment	19	-4.2
Response to Homoharringtonine (cytotoxicity)	32	-3.8
Response to iloperidone treatment (QT prolongation)	12	-1.4
Response to inhaled corticosteroid treatment in asthma (change in FEV1)	60	-5.2
Response to inhaled glucocorticoid treatment in asthma (change in FEV1)	11	-2.8
Response to interferon beta in multiple sclerosis	26	-2.5
Response to interferon beta therapy	5	-4.0
Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer	14	-2.7
Response to irinotecan in non-small-cell lung cancer	1	0.0
Response to ketamine in bipolar disorder or major depression (antidepressant effects)	12	-2.4
Response to ketamine in bipolar disorder or major depression (dissociation effects)	36	-7.0
Response to ketogenic dietary therapies in epilepsy	7	-3.4
Response to lithium treatment in bipolar disorder	22	-3.6
Response to long-chain n-3 polyunsaturated fatty acid supplementation (change in triglyceride levels)	49	-4.6
Response to long-term oxygen therapy in chronic obstructive pulmonary disease	44	-3.0
Response to lurasidone in schizophrenia	43	-3.8
Response to mepolizumab in severe asthma	53	-5.2
Response to metformin (IC50)	50	-3.4
Response to methotrexate in juvenile idiopathic arthritis	106	-5.1
Response to methotrexate in rheumatoid arthritis	5	-2.8
Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	6	-3.8
Response to montelukast in asthma (change in FEV1)	11	-2.6
Response to mTOR inhibitor (everolimus)	45	-3.8
Response to mTOR inhibitor (rapamycin)	36	-6.1
Response to olanzapine in schizophrenia	32	-6.0
Response to opioid analgesics in cancer (pain decrease)	5	-4.2
Response to paliperidone in schizophrenia (CGI-S score)	94	-5.4
Response to paliperidone in schizophrenia (Multivariate)	62	-2.7
Response to paliperidone in schizophrenia (negative Marder score)	191	-2.8
Response to paliperidone in schizophrenia (PANSS score)	108	-3.6
Response to paliperidone in schizophrenia (positive Marder score)	162	-3.7
Response to perphenazine in schizophrenia	24	-4.8
Response to platinum-based agents	77	-5.3
Response to platinum-based chemotherapy (carboplatin)	102	-3.1
Response to platinum-based chemotherapy (cisplatin)	91	-5.8
Response to platinum-based chemotherapy in non-small-cell lung cancer	8	-3.7
Response to platinum-based neoadjuvant chemotherapy in cervical cancer	7	-2.4
Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels)	14	-2.6
Response to quetiapine in schizophrenia	16	-5.4
Response to radiotherapy in cancer (late toxicity)	96	-4.8
Response to radiotherapy in prostate cancer (overall toxicity)	25	-2.4
Response to radiotherapy in prostate cancer (toxicity, rectal bleeding)	3	-3.4
Response to radiotherapy in prostate cancer (toxicity, urinary frequency)	20	-2.5
Response to ranibizumab in age-related macular degeneration (exudative)	3	-4.1
Response to risperidone in schizophrenia	4	-5.8
Response to selective serotonin reuptake inhibitors and depression	55	-5.2
Response to selective serotonin reuptake inhibitors in depression	20	-4.8
Response to serotonin reuptake inhibitors in major depressive disorder	85	-2.5
Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	33	-4.7
Response to serotonin reuptake inhibitors in non-psychotic unipolar depression	53	-4.0
Response to simvastatin treatment (PCSK9 protein level change)	22	-2.7
Response to SSRI in MDD or openness	11	-3.5
Response to SSRI (symptom remission)	17	-3.1
Response to statins (HDL cholesterol change)	4	-2.2
Response to statins (LDL cholesterol change)	47	-5.6
Response to statin therapy	199	-3.3
Response to tamoxifen in breast cancer	8	-4.4
Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer	1	0.0
Response to taxane treatment (docetaxel)	78	-6.5
Response to taxane treatment (placlitaxel)	25	-2.9
Response to temozolomide	27	-4.1
Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine)	2	-2.2
Response to TNF-alpha inhibitors in rheumatoid arthritis	62	-3.5
Response to TNF antagonist treatment	84	-3.9
Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score)	3	-3.8
Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score)	2	-5.6
Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)	122	-16.7
Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)	61	-4.4
Response to tocilizumab in rheumatoid arthritis	148	-4.7
Response to treatment for acute lymphoblastic leukemia	103	-4.7
Response to Vitamin E supplementation	2	-2.2
Response to zileuton treatment in asthma (FEV1 change interaction)	64	-2.8
Response to ziprazidone in schizophrenia	12	-2.8
Resting heart rate	478	-24.4
Resting metabolic rate	13	-4.0
Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry)	2	-1.4
Resting-state electroencephalogram vigilance	99	-3.0
Restless legs syndrome	135	-2.9
Reticulocyte count	544	-13.0
Reticulocyte fraction of red cells	553	-22.0
Retinal arteriolar caliber	14	-3.3
Retinal vascular caliber	8	-5.3
Retinopathy in non-diabetics	12	-5.2
Rheumatic fever	61	-4.5
Rheumatic heart disease	14	-7.5
Rheumatoid arthritis	787	-21.1
Rheumatoid arthritis (ACPA-negative)	31	-3.4
Rheumatoid arthritis (ACPA-positive)	193	-8.9
Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)	31	-3.7
Rheumatoid factor seropositivity in rheumatoid arthritis	7	-3.1
Right lateral prefrontal cortical growth	111	-5.6
Risk-taking tendency (4-domain principal component model)	505	-4.3
Risky sexual behaviors (alcohol dependence interaction)	38	-3.0
Risky sexual behaviors in alcohol dependence	35	-4.6
Rosacea symptom severity	205	-4.3
Rotator cuff tears	5	-2.6
RR interval (heart rate)	151	-4.2
Rubella	94	-3.6
Rumination (response to stress)	45	-2.6
Sagittal craniosynostosis	10	-3.4
Sarcoidosis	5	-3.8
Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)	3	-4.0
Sarcoidosis (non-Lofgren's syndrome without extrapulmonary manifestations)	7	-2.5
Sasang constitutional medicine type (So-Eum)	30	-7.9
Scalp hair shape	26	-2.0
Scarlet fever	154	-4.4
Schizophrenia	4258	-7.8
Schizophrenia (age at onset)	95	-4.4
Schizophrenia, bipolar disorder and depression (combined)	12	-4.8
Schizophrenia (cytomegalovirus infection interaction)	20	-5.4
Schizophrenia (inflammation and infection response interaction)	14	-3.8
Schizophrenia (negative symptoms)	3	-2.1
Schizophrenia or bipolar disorder	6	-2.9
Schizophrenia, schizoaffective disorder or bipolar disorder	2	-2.2
Schizophrenia (treatment resistant)	38	-5.4
Schizophrenia vs type 2 diabetes	35	-2.6
Sciatica caused by lumbar disc herniation (treated with microdiscectomy)	4	-9.8
Sclerosing cholangitis and ulcerative colitis (combined)	1	-1.7
Seasonality	42	-3.2
Seasonality and depression	66	-3.8
Seborrheic dermatitis	43	-3.5
Sedentary behaviour duration	25	-5.2
Select biomarker traits	143	-4.3
Selective IgA deficiency	193	-7.6
Self-employment	3	-4.6
Self-rated health	60	-3.3
Self-reported allergy	229	-9.8
Self-reported childhood asthma in adult smokers	14	-3.9
Self-reported math ability	2544	-5.2
Self-reported math ability (MTAG)	3790	-6.6
Self-reported risk-taking behaviour	218	-4.9
Self-reported tiredness	4	-4.6
Sensation seeking	15	-3.2
Sense of smell	55	-8.8
Sensory disturbances after bilateral sagittal split ramus osteotomy	6	-2.9
Sepsis from pneumonia (survival)	4	-3.3
Sepsis in extremely premature infants	9	-3.2
Sero-negative rheumatoid arthritis	7	-4.3
Serous borderline ovarian cancer	2	-2.4
Serous invasive ovarian cancer	17	-3.3
Serum 25-Hydroxyvitamin D levels	60	-4.3
Serum albumin level	76	-3.8
Serum alkaline phosphatase levels	135	-8.1
Serum bilirubin levels in metabolic syndrome	25	-3.9
Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome	99	-2.5
Serum bilirubin levels x sex interaction in metabolic syndrome	82	-3.0
Serum creatinine levels	10	-4.0
Serum dimethylarginine levels (asymmetric/symetric ratio)	64	-3.1
Serum folate levels	52	-4.8
Serum galactose-deficient IgA1 levels	10	-2.7
Serum lycopene concentrations	11	-3.1
Serum metabolite concentrations in chronic kidney disease	73	-3.5
Serum metabolite levels	188	-4.3
Serum metabolite ratios in chronic kidney disease	23	-4.2
Serum parathyroid hormone levels	9	-8.3
Serum prostate-specific antigen levels	8	-4.1
Serum protein levels (sST2)	7	-2.1
Serum selenium levels	7	-4.0
Serum sulfate level	65	-4.9
Serum tamsulosin hydrochloride concentration	28	-1.5
Serum thyroid-stimulating hormone levels	147	-3.8
Serum total cholesterol levels	20	-2.4
Serum total protein level	130	-5.6
Serum urate levels in chronic kidney disease	4	-2.0
Serum urea levels	20	-6.3
Serum uric acid levels	287	-7.3
Serum uric acid levels in response to allopurinol in gout	51	-2.5
Serum VEGFR2 concentration	1	0.0
Serum vitamin D-binding protein levels	10	-2.9
Severe aortic features in Marfan syndrome	19	-5.6
Severe depressive disorders in coronary artery disease	5	-1.1
Severe diabetic retinopathy in type 2 diabetes	6	-2.6
Severe gingival inflammation	14	-2.0
Severe influenza A (H1N1) infection	173	-5.0
Severe malaria	85	-3.6
Severe malaria (adjusted for sickle cell variant rs334)	44	-2.0
Severe progression in rheumatoid arthritis	3	-3.0
Severe skin toxicity response to cetuximab in colorectal cancer	50	-4.3
Severity of facial solar lentigines	15	-3.4
Severity of nausea and vomiting of pregnancy	36	-16.3
Sex hormone-binding globulin levels	69	-4.0
Sex hormone levels	28	-2.8
Sexual dimorphism in anthropometric traits	92	-2.7
Sexual dysfunction (female)	31	-5.3
Sexual dysfunction (SSRI/SNRI-related)	66	-5.5
Shingles	161	-4.2
Short-term memory (digit-span task)	26	-3.4
Short-term memory (visuospatial task)	17	-1.8
Sickle cell anemia (haemolysis)	13	-2.9
Sight-threatening diabetic retinopathy in type 2 diabetes	5	-4.3
Sitting height ratio	168	-4.8
Sjogren's syndrome	71	-3.8
Skin aging (microtopography measurement)	23	-4.5
Skin and soft tissue Staphylococcus aureus infection	1	-1.8
Skin colour saturation	2	-2.0
Skin fluorescence in type 1 diabetes	3	-2.2
Skin, hair and eye pigmentation (multivariate analysis)	38	-4.0
Skin pigmentation	67	-2.9
Skin pigmentation traits	2	-2.0
Sleep depth	15	-4.0
Sleep duration	898	-4.6
Sleep duration (long sleep)	39	-6.3
Sleep duration (oversleepers vs undersleepers)	27	-5.8
Sleep duration (short sleep)	118	-3.1
Sleep latency	1	-2.2
Sleep quality	7	-2.7
Sleep-related phenotypes	28	-2.9
Sleep time	10	-4.3
Sleep traits (multi-trait analysis)	37	-5.1
Small-cell lung cancer (survival)	2	-1.8
Small cell lung carcinoma	128	-2.4
Small intestine neuroendocrine tumor	28	-6.2
Small LDL particle concentration	8	-3.1
Small vessel stroke	18	-3.1
Smoking behavior	254	-3.3
Smoking behaviour (cigarettes smoked per day)	185	-3.4
Smoking behaviour (maximum cigarettes in a 24 hour period)	93	-3.7
Smoking cessation	132	-5.6
Smoking cessation in chronic obstructive pulmonary disease	23	-3.9
Smoking cessation (MTAG)	489	-10.7
Smoking initiation	358	-3.9
Smoking initiation (ever regular vs never regular) (MTAG)	4040	-9.6
Smoking initiation (ever regular vs never regular)	2647	-7.9
Smoking quantity	28	-5.0
Smoking status	1143	-3.9
Smoking status (current vs former)	1	-2.8
Smoking status (ever vs never smokers)	1739	-5.4
Smoking status (heavy vs light)	31	-2.4
Smooth-surface caries	186	-4.3
Snoring	200	-7.8
Social autistic-like traits	22	-5.5
Social communication problems	73	-4.6
Social science traits (pleiotropy) (HIPO component 1)	51	-2.9
Sodium levels	40	-3.8
Soluble E-selectin levels	7	-3.8
Soluble ICAM-1	4	-3.2
Soluble interleukin-2 receptor subunit alpha	45	-10.3
Soluble levels of adhesion molecules	4	-3.1
Speech perception in dyslexia	5	-5.0
Sperm motility	2	-2.9
S-phenylmercapturic acid levels in smokers	8	-4.9
Spherical equivalent	161	-3.8
Spherical equivalent (joint analysis main effects and education interaction)	72	-3.3
Spherical equivalent or myopia (age of diagnosis)	713	-3.3
Sphingolipid levels	25	-3.5
Spine bone size	8	-4.0
Spontaneous dizygotic twinning	21	-6.2
Spontaneous preterm birth (maternal effect)	12	-3.1
Spontaneous preterm birth (preterm birth)	53	-4.1
Spontaneous preterm birth (preterm delivery)	3	-1.6
Sporadic neuroblastoma	21	-3.8
Sporadic pituitary adenoma	11	-4.6
Squamous cell carcinoma	34	-2.9
Squamous cell lung carcinoma	143	-4.3
Staphylococcus aureus infection	21	-9.5
Staphylococcus aureus nasal carriage (intermittent)	64	-4.4
Staphylococcus aureus nasal carriage (persistent)	35	-4.6
Stearic acid (18:0) levels	27	-3.6
Stem cell factor levels	93	-5.4
Stem cell growth factor beta levels	109	-3.2
Stimulated C-peptide levels in type I diabetes	5	-2.8
Strenuous sports or other exercises	29	-6.5
Strep throat	98	-15.5
Stroke	286	-5.1
Stroke (ischemic)	71	-6.1
Stroke (pediatric)	23	-4.5
Stromal-cell-derived factor 1 alpha levels	74	-4.2
Subclinical atherosclerosis traits (other)	23	-4.2
Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)	6	-3.0
Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)	4	-3.7
Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan)	1	-3.6
Subcortical brain region volumes	129	-3.9
Subcutaneous adipose tissue	246	-5.3
Subcutaneous adipose tissue attenuation (Hounsfield unit scale)	7	-3.6
Subcutaneous adipose tissue (sex interaction)	2	-2.5
Subiculum volume	7	-3.1
Subiculum volume (corrected for total hippocampal volume)	15	-2.3
Subjective response to lithium treatment	8	-3.7
Subjective response to lithium treatment in bipolar disorder	16	-6.1
Subjective well-being	412	-4.6
Subjective well-being (MTAG)	246	-4.9
Substance dependence	8	-2.0
Substance use disorder	16	-2.9
Sudden cardiac arrest	175	-4.7
Suffering from nerves	29	-5.2
Suicidal ideation	135	-5.2
Suicidality	24	-2.3
Suicidality (suicidal ideation/attempts)	2	-2.4
Suicide	10	-2.1
Suicide attempts	181	-2.5
Suicide attempt severity	5	-1.6
Suicide attempts in bipolar disorder	50	-3.4
Suicide attempts in depression or bipolar disorder	3	-4.1
Suicide attempts in major depressive disorder	18	-3.7
Suicide ideation score in major depressive disorder	11	-2.8
Suicide in bipolar disorder	47	-2.4
Suicide risk	9	-3.7
Sulfasalazine-induced agranulocytosis	64	-5.3
Sum basophil neutrophil counts	379	-12.6
Sum eosinophil basophil counts	595	-18.8
Sum neutrophil eosinophil counts	386	-13.9
Sunburns	306	-3.9
Superior crus of antihelix expression	16	-4.3
Superior frontal gyrus grey matter volume	74	-3.2
Supraventricular ectopy	29	-2.4
Surgical necrotising enterocolitis in extremely premature birth	69	-2.6
Survival in breast cancer (estrogen-receptor positive)	17	-3.2
Survival in colon cancer	30	-5.8
Survival in colorectal cancer (non-distant metastatic)	6	-3.7
Survival in colorectal cancer	7	-2.0
Survival in endocrine treated breast cancer (estrogen-receptor positive)	10	-2.2
Survival in head and neck cancer	19	-2.2
Survival in microsatellite instability low/stable colorectal cancer	115	-5.4
Survival in pancreatic cancer	117	-2.0
Survival in rectal cancer	132	-3.9
Survival in sporadic amyotrophic lateral sclerosis	40	-5.0
Susceptibility to persistent hepatitis B virus infection	10	-3.2
Symmetrical dimethylarginine levels	94	-2.9
Systemic juvenile idiopathic arthritis	136	-4.5
Systemic lupus erythematosus	1607	-28.8
Systemic lupus erythematosus and Systemic sclerosis	99	-6.5
Systemic lupus erythematosus or rheumatoid arthritis	28	-6.6
Systemic sclerosis	98	-4.2
Systemic sclerosis (anti-centromere-positive)	8	-3.0
Systemic sclerosis (anti-topoisomerase-positive)	4	-2.9
Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies)	52	-4.3
Systolic blood pressure	5756	-11.8
Systolic blood pressure (alcohol consumption interaction)	9	-2.8
Systolic blood pressure change trajectories	2	-5.5
Systolic blood pressure (cigarette smoking interaction)	265	-3.2
Systolic blood pressure (dietary potassium intake interaction)	13	-3.3
Systolic blood pressure in sickle cell anemia	14	-3.3
Systolic blood pressure night-to-day ratio in hypertension	3	-1.5
Systolic blood pressure response to hydrochlorothiazide in hypertension	119	-6.3
Systolic blood pressure x alcohol consumption interaction (2df test)	380	-6.5
Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)	122	-8.5
Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)	10	-3.1
Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	196	-3.8
Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	176	-4.3
Systolic blood pressure x sodium interaction (1df test)	8	-4.3
Takayasu arteritis	126	-7.6
Takotsubo syndrome	36	-5.7
Tandem gait	4	-2.8
Tanning	43	-2.5
Tardive dyskinesia	3	-1.7
Taxane-induced peripheral neuropathy in breast cancer	19	-2.7
TB-LM or TBLH-BMD (pleiotropy)	55	-4.2
Telomere length	264	-6.5
Temperament (bipolar disorder)	67	-8.0
Temperament	116	-5.5
Temporomandibular joint disorder	10	-2.7
Tenofovir clearance in HIV infection	148	-4.5
Testicular cancer	2	-5.5
Testicular germ cell cancer	3	-5.1
Testicular germ cell tumor	114	-6.6
Testosterone levels	14	-2.9
Testosterone levels in polycystic ovary syndrome	49	-5.4
Tetralogy of Fallot	15	-3.2
Theory of mind score in adolescence (Emotional Triangles Task)	1	-3.4
Thiazide-induced adverse metabolic effects in hypertensive patients	321	-3.3
Thionamide-induced agranulocytosis in Graves' disease	16	-6.0
Thiopurine-induced alopecia in inflammatory bowel disease	3	0.0
Thiopurine-induced digestive symptoms in inflammatory bowel disease	1	-2.0
Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232)	2	-3.4
Thiopurine-induced pancreatitis in inflammatory bowel disease	4	-2.2
Thiopurine S-methyltransferase activity	10	-4.4
Thoracic-to-hip circumference ratio	2	-3.1
Thrombin-activatable fibrinolysis inhibitor activation peptide	10	-3.4
Thrombin-activatable fibrinolysis inhibitor levels	1	-2.8
Thrombin-antithrombin complex levels in ischemic stroke	44	-2.9
Thrombin generation potential phenotypes	5	-3.7
Thrombocytopenia in coronary artery bypass surgery	16	-2.6
Thrombomodulin levels in ischemic stroke	20	-4.6
Thrombosis	15	-4.3
Thyroid cancer	25	-5.5
Thyroid cancer (Papillary, radiation-related)	17	-3.4
Thyroid function	42	-2.9
Thyroid hormone levels	198	-6.8
Thyroid nodules	5	-2.2
Thyroid peroxidase antibody levels	12	-5.5
Thyroid peroxidase antibody positivity	70	-14.7
Thyroid stimulating hormone levels	167	-10.3
Thyroid volume	14	-3.0
Thyrotoxic hypokalemic periodic paralysis	55	-5.9
Thyroxine levels	2	-2.4
Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor	2	-3.4
Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)	241	-5.5
Toenail selenium levels	90	-2.9
Tonometry	28	-4.6
Tonsillectomy	423	-4.7
Tooth agenesis	1	-1.8
Tooth agenesis (mandibular second premolars)	2	-2.9
Tooth agenesis (mandibular third molar)	23	-3.9
Tooth agenesis (maxillary lateral incisors)	27	-4.3
Total bilirubin levels	17	-9.4
Total bilirubin levels in HIV-1 infection	5	-3.8
Total body bone mineral density	700	-5.0
Total body bone mineral density (age 0-15)	29	-5.6
Total body bone mineral density (age 30-45)	59	-5.7
Total body bone mineral density (age 45-60)	74	-5.4
Total body bone mineral density (age over 60)	121	-4.8
Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes	37	-2.3
Total cholesterol levels	747	-10.4
Total cholesterol levels in HDL	9	-5.2
Total cholesterol levels in large HDL	1	-2.9
Total cholesterol levels in large LDL	4	-3.0
Total cholesterol levels in LDL	6	-3.6
Total cholesterol levels in medium LDL	5	-2.9
Total cholesterol levels in small LDL	8	-3.1
Total glycated albumin levels	24	-4.0
Total hippocampal volume	12	-4.3
Total mean fractional anisotropy measurement in first episode schizophrenia	7	-3.8
Total triglycerides levels	1	-2.8
Total ventricular volume	36	-4.2
Total ventricular volume (Alzheimer's disease interaction)	32	-4.0
Tourette's syndrome or obsessive-compulsive disorder	14	-1.8
Tourette syndrome	86	-4.1
Tragus size	5	-4.0
TRAIL levels	124	-3.6
Trans-epidermal water loss	2	-2.5
Trans fatty acid levels	230	-4.8
Treatment resistant depression	7	-3.0
Treatment response for severe sepsis	23	-4.2
Trichloroethylene-induced hypersensitivity syndrome	2	-2.5
Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes	33	-2.4
Triglyceride levels	388	-6.9
Triglyceride levels in small VLDL	1	-2.8
Triglycerides	959	-9.2
Triglycerides-Blood Pressure (TG-BP)	28	-5.6
Triglycerides x physical activity interaction (2df test)	35	-5.7
Triglyceride to HDL cholesterol ratio	3	-2.6
Triiodothyronine levels	8	-6.6
Triiodothyronine levels and thyroxine levels	15	-3.7
Triiodothyronine/thyroxine ratio	6	-2.3
Triptolide cytotoxicity	68	-5.2
Tuberculosis	289	-3.2
Tumor biomarkers	3	-4.2
Tumor necrosis factor alpha levels	66	-4.9
Tumor necrosis factor beta levels	17	-2.1
Tumor necrosis factor receptor II (red blood cell fatty acid level interaction)	2	-1.3
Two-hour glucose challenge	38	-4.7
Two-hour glucose in pregnancy (gestational week 30-32)	19	-4.8
Type 1 diabetes	240	-13.0
Type 1 diabetes and autoimmune thyroid diseases	21	-4.9
Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)	6	-2.0
Type 1 diabetes in high risk HLA genotype individuals (time to event)	22	-2.8
Type 1 diabetes nephropathy	18	-4.8
Type 2 diabetes	2082	-4.4
Type 2 diabetes (age of onset)	123	-2.6
Type 2 diabetes (dietary heme iron intake interaction)	4	-2.4
Type 2 diabetes nephropathy	32	-6.2
Type 2 diabetes nephropathy including microalbuminuria	41	-7.7
Type 2 diabetes (young onset) and obesity	3	-5.5
Ulcerative colitis	821	-12.1
Ulcerative colitis or Crohn's disease	18	-3.6
Ulna and radius bone mineral density	15	-5.5
Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic)	1	-1.8
Underweight status	5	-2.3
Upper eyelid morphology	52	-3.3
Upper eyelid sagging severity	117	-7.3
Urate levels	199	-6.0
Urate levels (BMI interaction)	225	-7.1
Urate levels in lean individuals	45	-2.5
Urate levels in obese individuals	143	-3.5
Urate levels in overweight individuals	135	-4.3
Urea levels	45	-4.7
Urgency urinary incontinence	8	-1.6
Uric acid levels	278	-3.3
Urinary 1,3-butadiene metabolite levels in smokers	2	-3.0
Urinary albumin excretion	116	-3.8
Urinary albumin excretion (no hypertensive medication)	45	-3.8
Urinary albumin excretion rate in type 1 diabetes	6	-3.0
Urinary albumin-to-creatinine ratio	33	-3.7
Urinary albumin-to-creatinine ratio in diabetes	7	-5.7
Urinary albumin-to-creatinine ratio in non-diabetics	6	-3.0
Urinary bladder cancer	10	-3.6
Urinary electrolytes (magnesium/calcium ratio)	17	-3.6
Urinary magnesium-to-creatinine ratio	8	-4.0
Urinary metabolite concentrations in chronic kidney disease	14	-2.8
Urinary metabolites	13	-4.1
Urinary metabolites (H-NMR features)	9	-4.5
Urinary tract infection frequency	108	-6.3
Urinary uric acid to urinary creatinine ratio	29	-3.9
Urinary uromodulin levels	5	-1.9
Uterine fibroid number (single vs multiple)	43	-3.6
Uterine fibroids	144	-3.4
Uterine fibroid size (maximum dimension)	2	-1.5
Uterine fibroid size (maximum volume)	11	-3.3
Uveal melanoma	2	-2.4
Vaccenic acid (18:1n-7) levels	1	-3.6
Vaccine-related adverse events	2	0.0
Vaginal discharge (itching)	7	-2.7
Vaginal discharge (metrorrhagia)	2	-2.7
Vaginal discharge (smell)	48	-5.9
Varicose veins	102	-5.7
Vascular brain injury	19	-3.1
Vascular endothelial growth factor levels	103	-4.6
Vasculitis associated with antineutrophil cytoplasmic antibody reactive to myeloperoxidase	1	-2.5
Vaspin levels	5	-2.9
Vein graft stenosis in coronary artery bypass grafting	20	-4.4
Velopharyngeal dysfunction	317	-6.0
Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks)	19	-4.8
Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)	8	-4.1
Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks)	5	-2.3
Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)	1	-2.0
Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)	39	-4.1
Venous thromboembolism	43	-5.2
Venous thromboembolism adjusted for sickle cell variant rs77121243-T	252	-2.6
Ventricular ectopy	4	-2.4
Ventricular ectopy or supraventricular ectopy (pleiotropy)	16	-2.7
Verbal declarative memory	142	-5.9
Verbal intelligence quotient (cesarean section interaction)	15	-7.4
Verbal memory	5	-1.6
Verbal memory performance (delayed recall level)	1	-1.7
Verbal memory performance (immediate recall change)	20	-4.0
Verbal memory performance (immediate recall level)	72	-6.0
Verbal memory performance (residualized delayed recall change)	13	-3.1
Verbal memory performance (residualized delayed recall level)	12	-4.7
Verbal-numerical reasoning	36	-2.4
Vertical cup-disc ratio	241	-4.6
Very long-chain saturated fatty acid levels (fatty acid 20:0)	53	-3.4
Very long-chain saturated fatty acid levels (fatty acid 22:0)	59	-3.1
Very long-chain saturated fatty acid levels (fatty acid 24:0)	13	-4.5
Very low density lipoprotein cholesterol levels	2	-2.6
Vestibular neuritis	3	-0.9
Vigorous physical activity	7	-3.2
Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	19	-2.3
Viral capsid antigen IgG seropositivity	7	-2.2
Virologic severity in Herpes simplex virus type 2 infection	22	-3.5
Visceral adipose tissue	32	-3.5
Visceral adipose tissue adjusted for BMI	207	-5.2
Visceral adipose tissue attenuation (Hounslow unit scale)	7	-3.6
Visceral adipose tissue/subcutaneous adipose tissue ratio	155	-3.7
Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI	15	-5.1
visceral adipose tissue/total adipose tissue ratio	16	-2.5
Visceral fat	298	-3.9
Visual memory	3	-4.2
Vitamin B12 levels	63	-3.5
Vitamin B levels in ischemic stroke	11	-3.2
Vitamin D levels	94	-4.0
Vitamin D levels (dietary vitamin D intake interaction)	2	-6.0
Vitamin E levels	16	-9.6
Vitiligo	85	-5.4
Vitiligo (early onset)	4	-7.7
Vitiligo (late onset)	3	-5.1
Vogt-Koyanagi-Harada syndrome	42	-5.0
Volumetric brain MRI	53	-3.8
Voxel-wise structural brain imaging measurements	5	-2.8
vWF and FVIII levels	69	-4.6
vWF levels	39	-5.6
vWF levels in ischaemic stroke and hyperhomocysteinaemia	3	-3.3
Waist circumference	744	-4.6
Waist circumference adjusted for BMI (adjusted for smoking behaviour)	415	-5.5
Waist circumference adjusted for BMI in active individuals	416	-6.3
Waist circumference adjusted for BMI in inactive individuals	69	-5.4
Waist circumference adjusted for BMI in non-smokers	321	-6.0
Waist circumference adjusted for BMI in smokers	11	-4.1
Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	445	-6.1
Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)	414	-5.5
Waist circumference adjusted for BMI (smoking interaction)	3	-2.7
Waist circumference adjusted for body mass index	956	-6.5
Waist circumference and related phenotypes	32	-5.0
Waist-hip ratio	2643	-11.3
Waist-to-hip circumference ratio (alcohol intake interaction)	30	-6.1
Waist-to-hip circumference ratio (dietary energy interaction)	3	-2.2
Waist-to-hip circumference ratio (ever vs never smoking interaction)	40	-2.5
Waist-to-hip circumference ratio (recreational physical activity interaction)	17	-4.3
Waist-to-hip circumference ratio (smoking years interaction)	29	-2.3
Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)	406	-8.2
Waist-to-hip ratio adjusted for BMI (age <50)	103	-5.8
	126	-7.0
Waist-to-hip ratio adjusted for BMI in active individuals	328	-7.0
Waist-to-hip ratio adjusted for BMI in inactive individuals	83	-5.7
Waist-to-hip ratio adjusted for BMI in non-smokers	168	-8.1
Waist-to-hip ratio adjusted for BMI in smokers	22	-4.2
Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	371	-6.6
Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)	166	-8.2
Waist-to-hip ratio adjusted for BMI	1069	-6.8
Waist-to-hip ratio adjusted for BMI x sex interaction	178	-4.4
Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	444	-7.9
Waist-to-hip ratio adjusted for body mass index	567	-7.0
Waldenstrom macroglobulinemia / lymphoplasmacytic lymphoma	3	-1.3
Warfarin maintenance dose	61	-3.6
Wegener's granulomatosis	38	-4.7
Weight	556	-5.1
Weight loss (gastric bypass surgery)	15	-1.9
Well-being spectrum (multivariate analysis)	1424	-5.6
Western dietary pattern	54	-3.0
White blood cell count	2763	-29.9
White blood cell count (basophil)	177	-18.4
White blood cell count (eosinophil)	17	-3.8
White blood cell count (lymphocyte)	1	-2.6
White blood cell count (monocyte)	8	-6.2
White blood cell count (neutrophil)	2	-3.1
White blood cell types	41	-3.9
White matter growth	12	-3.0
White matter hyperintensities in ischemic stroke	8	-2.1
White matter hyperintensity burden	105	-3.1
White matter hyperintensity volume	24	-3.7
White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy	19	-3.6
White matter integrity	76	-4.2
White matter integrity (bipolar disorder risk interaction)	23	-2.5
White matter lesion progression	11	-2.2
White matter lesion progression (adjusted for white matter lesion burden at baseline)	26	-4.3
White matter microstructure (global fractional anisotropy)	64	-2.8
White matter microstructure in first episode schizophrenia (left posterior cingulate cortex)	3	-5.2
White matter microstructure in first episode schizophrenia (right anterior cingulate cortex)	3	-4.6
White wine liking	3	-4.6
Whole-brain volume	101	-3.4
Whole-brain volume (Alzheimer's disease interaction)	22	-4.6
Wilms tumor	27	-8.7
Word reading	113	-3.3
Word spelling	93	-7.8
Working memory	32	-3.8
World class endurance athleticism	35	-4.1
Worry	657	-4.0
Worry too long after an embarrassing experience	41	-2.3
Worry/vulnerability (special factor of neuroticism)	46	-4.0
Yang-deficiency constitution	8	-3.7
Yeast infection	105	-4.1
Yu-Zhi constitution type in type 2 diabetes	44	-4.3
Albuminuria	11	-4.7
Alzheimer's disease or fasting glucose levels (pleiotropy)	38	-2.5
Alzheimer's disease or HDL levels (pleiotropy)	32	-6.6
Anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis	39	-3.5
Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis	44	-2.9
Anti-thyroid peroxidase (TPOAb) levels in Hashimoto's thyroiditis	17	-3.3
Anti-Toxoplasma gondii IgG seropositivity	15	-5.5
Asthma (adult onset)	216	-7.7
Asthma onset (childhood vs adult)	251	-7.2
Carbamazepine-induced hyponatremia in epilepsy	24	-2.8
Carbamazepine metabolism (carbamazepine-10,11-diol to carbamazepine ratio) in epilepsy	9	-1.8
Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy	15	-2.7
Colorectal cancer or advanced adenoma	499	-6.5
Emotional lability in attention deficit hyperactivity disorder	10	-2.2
Facial attractiveness (female raters)	15	-3.2
Facial attractiveness (male raters)	16	-4.7
Frontal fibrosing alopecia	115	-4.8
Homeostasis model assessment of insulin resistance in less-fat diet	3	-2.6
Homeostasis model assessment of insulin resistance in more-fat diet	4	-3.4
Homeostasis model assessment of insulin resistance x saturated fatty acids interaction	3	-2.6
Hyperglycemia in higher physical activity	4	-3.0
Hyperinsulinemia in lower physical activity	6	-1.7
Hyperinsulinemia in obesity	28	-3.3
Hyperinsulinemia x BMI interaction	1	0.0
Hyperinsulinemia x physical activity interaction	6	-1.7
Incident chronic kidney disease	12	-2.5
Latent naming speed	12	-4.4
Medication use (adrenergics, inhalants)	252	-8.3
Medication use (agents acting on the renin-angiotensin system)	1076	-4.8
Medication use (anilides)	4	-2.3
Medication use (antidepressants)	1	-1.9
Medication use (antiglaucoma preparations and miotics)	36	-3.3
Medication use (antihistamines for systemic use)	85	-7.0
Medication use (antihypertensives)	5	-5.1
Medication use (anti-inflammatory and antirheumatic products, non-steroids)	31	-4.5
Medication use (antimigraine preparations)	135	-3.6
Medication use (antithrombotic agents)	2	-1.2
Medication use (beta blocking agents)	320	-4.1
Medication use (calcium channel blockers)	577	-5.6
Medication use (diuretics)	568	-4.6
Medication use (drugs affecting bone structure and mineralization)	84	-5.3
Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease)	8	-2.4
Medication use (drugs used in diabetes)	282	-4.0
Medication use (glucocorticoids)	87	-8.3
Medication use (HMG CoA reductase inhibitors)	283	-9.4
Medication use (salicylic acid and derivatives)	4	-2.6
Medication use (thyroid preparations)	444	-11.7
Medication use (vasodilators used in cardiac diseases)	1	-3.5
Monoclonal gammopathy of undetermined significance	5	-2.7
Mouth ulcers	204	-14.7
Oxcarbazepine-induced hyponatremia in epilepsy	2	-1.4
Primary central nervous system lymphoma	6	-6.4
Psychological resilience (outcome-based)	25	-3.6
Psychological resilience (outcome-based) in high deployment stress exposure	22	-7.9
Psychological resilience (self-assessed)	19	-2.4
Rapid alternating stimulus test for letters/numbers	15	-2.7
Rapid automised naming and rapid alternating stimulus test performance	15	-2.7
Right-sided colonic diverticulosis	12	-2.9
Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy	28	-3.4
Skin reflectance (Melanin index)	191	-2.7
Sleep (number of episodes)	12	-1.9
Sodium levels in epilepsy	4	-2.8
Tinnitus in cisplatin-treated testicular cancer	18	-3.3
Trunk fat mass adjusted for trunk lean mass	13	-3.9
Type 2 diabetes and end-stage kidney disease	24	-2.3
Type 2 diabetes and end-stage kidney disease in APOL1 risk genotype negative individuals	10	-3.7
Urolithiasis	25	-6.3
Accommodative esotropia	56	-1.9
Airway obstruction (FEV1/FVC<70) in never smokers	9	-2.2
Alanine aminotransferase levels in non-alcoholic fatty liver disease	90	-3.2
Alcohol dependence or heroin dependence or methamphetamine dependence	11	-8.2
Alcohol dependence (time spent drinking)	2	-1.9
Alcohol use disorder	186	-4.5
Alcohol withdrawal symptoms	4	-3.7
Allergic rhinitis x sex interaction	12	-6.5
Alzheimer's disease in hypertension	22	-2.5
Alzheimer's disease in hypertension-negative individuals	13	-2.0
Amblyopia	45	-5.9
Annualised percent change of cerebrospinal fluid AB1-42 levels	12	-5.3
Anti-adalimumab antibody production in response to treatment in Crohn's disease	25	-4.7
Anxiety and stress-related disorders	15	-3.5
Arterial stiffness index	89	-7.9
Artificially sweetened beverage consumption	13	-3.3
Aspartate aminotransferase levels in non-alcoholic fatty liver disease	71	-5.7
Asthma (age of onset)	62	-3.8
Atorvastatin-induced myopathy	16	-3.1
Atypical femoral fracture in phosphonate treatment	61	-5.5
Balance difficulty in Charcot-Marie-Tooth disease type 1A	16	-2.5
Benign prostatic hyperplasia	35	-2.9
Bipolar II disorder	27	-6.4
Bisphosphonate-associated atypical femoral fracture	53	-3.3
Bitter alcoholic beverage consumption	309	-2.8
Bitter beverage consumption	82	-3.6
Bitter non-alcoholic beverage consumption	67	-3.8
Bitter taste perception (6-n-propylthiouracil) in obesity with metabolic syndrome	86	-3.0
Bitter taste perception (phenylthiocarbamide) in obesity with metabolic syndrome	12	-3.2
Blood cell traits (multivariate analysis)	14	-3.8
Breakfast cereal skipping frequency	37	-3.5
Breakfast skipping	37	-3.5
Candidemia	31	-4.8
Cannabis use disorder	14	-2.6
Cardiac troponin-I levels	10	-4.1
Celiac disease and Rheumatoid arthritis	121	-7.1
Cerebral microbleed progression	2	-2.9
Cerebral microbleeds	8	-4.0
Cerebrospinal fluid sTREM-2 levels	4	-5.6
Change in neurofilament light levels	17	-4.2
Chronic lymphocytic leukemia or multiple sclerosis	33	-6.5
Chronic lymphocytic leukemia or systemic lupus erythematosus	48	-4.5
Chronic mountain sickness	12	-2.9
Cognitive ability in schizophrenia	8	-2.0
Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	1292	-4.0
Cognitive impairment	37	-3.9
Composite immunoglobulin trait (IgA/IgM)	11	-4.6
Composite immunoglobulin trait (IgA x IgG)	4	-2.9
Composite immunoglobulin trait (IgA x IgG/IgM)	16	-3.3
Composite immunoglobulin trait (IgA x IgG x IgM)	2	-1.4
Composite immunoglobulin trait (IgG/IgM)	15	-5.2
Corneal endothelial cell density	41	-5.1
Corneal endothelial cell shape (percentage of hexagonally shaped cells)	14	-3.0
Corneal endothelial cell size variation coefficient	63	-4.7
Corneal hysteresis	37	-9.5
Corneal resistance factor	18	-3.9
Decreased sensory function in Charcot-Marie-Tooth disease type 1A	13	-3.2
Dentures	101	-4.2
Diabetic maculopathy in type 2 diabetes	29	-2.5
Diabetic maculopathy with decreased visual acuity in type 2 diabetes	5	-2.1
Diabetic peripheral neuropathy in type 2 diabetes	8	-3.5
Diffuse large B-cell lymphoma or multiple sclerosis	22	-7.2
Diffuse large B-cell lymphoma or systemic lupus erythematosus	2	-1.1
Diverticulitis	97	-6.7
Early spontaneous preterm birth	34	-5.2
Emphysema annual change measurement in smokers (adjusted lung density)	162	-3.6
Emphysema annual change measurement in smokers (percent low attenuation area)	156	-4.4
End-stage kidney disease	33	-2.8
Epigenetic age acceleration in alcohol use disorder	31	-7.2
Esotropia	2	-6.4
Estimated glomerular filtration rate in diabetes	103	-3.7
Estimated glomerular filtration rate in non-diabetics	255	-4.2
Facial morphology traits (63 three-dimensional facial segments)	55	-3.2
Fagerstr?m test for nicotine dependence	9	-3.2
Fasting blood proinsulin levels	12	-3.2
Fasting glucose change	29	-4.8
Fasting glucose change (long-term)	49	-6.3
Fasting glucose change (short-term)	34	-7.2
Fish intake frequency	17	-7.1
Follicular lymphoma or multiple sclerosis	3	-3.1
Foot deformity in Charcot-Marie-Tooth disease 1A	9	-5.6
Foot plantar flexion strength in Charcot-Marie-Tooth disease 1A	1	0.0
Geographic atrophy lesion growth rate in age-related macular degeneration	35	-9.4
Glucosuria	35	-2.6
Glucosuria (mild)	35	-2.6
Glucosuria (moderate to severe)	35	-2.6
Glycemic traits (pleiotropy)	32	-2.7
Grapefruit juice consumption	4	-4.2
group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP	72	-4.1
HDL cholesterol levels in current drinkers	200	-7.9
HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	254	-6.8
HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	244	-6.5
Health literacy	59	-3.1
Hearing loss in Charcot-Marie-Tooth disease 1A	6	-2.1
Heart rate in heart failure with reduced ejection fraction	314	-3.3
Heel bone mineral density (MTAG)	41	-5.7
Hematuria	1	-2.7
Hematuria (moderate to severe)	1	-2.7
	18	-6.7
Intake of sweets	44	-6.4
Intake of total sugars	224	-4.1
Intertrochanteric region size	63	-4.8
Intraocular pressure (Goldman correlated)	1	-2.7
Knee pain	16	-2.2
LDL cholesterol levels in current drinkers	143	-6.5
LDL cholesterol levels in current smokers	4	-7.6
LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	160	-6.6
LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	155	-6.3
LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)	4	-7.6
LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)	4	-7.6
Leukocyte telomere length	10	-4.0
Liver fibrosis in non-alcoholic fatty acid liver disease	95	-4.1
	62	-5.1
	1	-2.1
Low susceptibility to hepatitis C infection	28	-2.5
Low urine pH	14	-3.1
Lung function in heavy smokers (low FEV1 vs high FEV1)	1	0.0
Lung function in never smokers (high FEV1 vs average FEV1)	9	-2.0
Lung function in never smokers (low FEV1 vs average FEV1)	15	-2.1
Lung function in never smokers (low FEV1 vs high FEV1)	141	-4.2
Lung function (low FEV1 vs high FEV1)	108	-4.9
Lung function (low FEV1 vs high FEV1) x smoking interaction	8	-4.2
Lymphangioleiomyomatosis (sporadic)	24	-3.4
Marginal zone lymphoma or multiple sclerosis	9	-3.5
Marginal zone lymphoma or rheumatoid arthritis	13	-2.6
Marginal zone lymphoma or systemic lupus erythematosus	72	-3.9
Maximum habitual alcohol consumption	141	-7.6
Meningococcal C functional antibody titers post childhood immunization	12	-2.4
Mental health study participation (completed survey)	43	-4.4
Mental health study participation (provided email address)	46	-3.6
Mild to moderate chronic kidney disease	17	-2.2
Moderate-to-late spontaneous preterm birth	56	-4.9
Morningness	1537	-4.8
Multisite chronic pain	86	-3.3
Neurological blood protein biomarker levels	104	-4.4
Neuropathy in Charcot-Marie-Tooth disease type 1A	3	-3.5
Non-accommodative esotropia	12	-4.5
Non-alcoholic fatty liver disease activity score	34	-2.6
Non-muscle-invasive bladder cancer tumour size	14	-3.6
Nonobstructive coronary artery disease	7	-3.1
Number of alcoholic drinks required to feel an effect (first five times drinking)	1	-3.1
Number of alcoholic drinks required to feel an effect (long-term average)	2	-1.8
Number of decayed, missing and filled tooth surfaces or use of dentures	101	-4.2
Occipital lobe volume	70	-6.9
Opioid overdose severity score	114	-2.5
Peginterferon alfa-2a treatment response in chronic hepatitis B infection	57	-7.1
Pemphigus	2	-5.1
Pepsinogen I/II ratio	65	-2.9
Perceived intensity of aspartame	47	-2.6
Perceived intensity of fructose	2	0.0
Perceived intensity of glucose	26	-3.7
Perceived intensity of neohesperidin dihydrochalcone	34	-2.8
Perceived intensity of sucrose	63	-5.0
Perceived intensity of sweet substances	12	-1.9
Perceived sweetness of sucrose	56	-2.8
Periodontal disease related phenotype (PCT3)	5	-4.1
Periodontal disease related phenotype (PCT4)	5	-2.1
Periodontal disease related phenotype (PCT5)	15	-2.1
Periodontal disease-related phenotype (Socransky)	111	-2.4
Phenylephrine infusion rate during anesthesia	45	-3.6
Plasma anti-thyroglobulin and anti-thyroid peroxidase levels (bivariate analysis)	37	-4.2
Plasma anti-thyroglobulin levels	83	-5.6
Plasma anti-thyroid peroxidase levels	118	-3.1
Plasma factor V levels in venous thrombosis	41	-3.2
Plasma factor V levels in venous thrombosis (conditioned on rs6027)	66	-3.0
Platelet reactivity measurement (collagen-epinephrine)	4	-3.1
Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma	15	-6.1
Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma	50	-7.2
Postoperative acute renal failure after cardiac surgery	4	-2.6
Postoperative atrial fibrillation after cardiac surgery	10	-4.8
Postoperative complication after cardiac surgery	5	-3.6
Postoperative delirium after cardiac surgery	19	-4.6
Postoperative myocardial infarction after cardiac surgery	6	-2.4
Postoperative stroke after cardiac surgery	68	-3.4
Post-traumatic stress disorder (re-experiencing symptoms)	55	-4.6
Post-traumatic stress disorder symptoms in trauma-exposed soldiers	34	-3.0
Predicted visceral adipose tissue	1151	-4.0
Pre-treatment viral load in HIV-1 infection	235	-2.8
Proliferative diabetic retinopathy	5	-3.6
Psychological wellbeing index 12 (lack of enjoying daily life)	7	-2.5
Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)	5	-4.7
Pure non-grapefruit juice consumption	31	-7.8
Response to allopurinol in gout (change in serum uric acid levels)	8	-4.5
Response to cognitive-behavioural therapy in anxiety and major depressive disorders	24	-5.1
Response to cognitive-behavioural therapy in major depressive disorder	25	-3.7
Response to direct-acting antiviral treatment in hepatitis C virus genotype 3	69	-4.0
Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease	1	-3.2
Response to interferon treatment in hepatitis C virus genotype 3	31	-4.1
Salty taste perception in obesity with metabolic syndrome	12	-4.3
same-sex sexual behaviour	13	-2.6
Schizoaffective disorder-bipolar type	14	-4.4
Scoliosis in Charcot-Marie-Tooth disease 1A	5	-3.1
Serum platinum levels after completion of cisplatin chemotherapy	93	-3.8
Simvastatin-induced myopathy	60	-2.9
Skin pigmentation (conditioned on rs1426654 and rs35397)	20	-2.8
Smoking status (heavy vs never)	54	-3.2
Sour taste perception in obesity with metabolic syndrome	11	-4.9
Spontaneous preterm birth without premature rupture of membranes	64	-3.0
Spontaneous preterm birth with premature rupture of membranes	25	-3.7
Statin-induced myopathy	5	-2.7
Statin-induced myopathy (severe)	7	-2.9
Stress sensitivity (neuroticism score x major depressive disorder status interaction)	116	-17.2
Sucrose liking	35	-2.6
Sugar-sweetened beverage consumption	23	-7.2
Suicide attempts in bipolar disorder or schizophrenia	72	-2.9
Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia	14	-2.5
Suicide attempts in schizophrenia	77	-2.6
Sweet beverage consumption	34	-7.0
Sweet taste perception in obesity with metabolic syndrome	10	-3.5
Taste perception (total score including phenylthiocarbamide) in obesity with metabolic syndrome	34	-3.0
Tea consumption	251	-2.0
Thyroglobulin plasma levels	17	-3.6
Thyrotoxic hypokalemic periodic paralysis and Graves disease	138	-8.6
Thyrotoxic hypokalemic periodic paralysis in Graves disease	88	-7.3
Time to smoke first cigarette in the morning	19	-5.5
Total body bone mineral density (MTAG)	70	-4.8
Toxicity response to radiotherapy in prostate cancer (decreased urine stream) (time to event)	74	-6.3
Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event)	33	-3.4
Toxicity response to radiotherapy in prostate cancer (increased urinary frequency) (time to event)	7	-2.6
Toxicity response to radiotherapy in prostate cancer (rectal bleeding) (time to event)	45	-2.8
Triglyceride levels in current drinkers	162	-4.6
Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	169	-4.4
Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	168	-4.5
Trochanter size	3	-2.4
Trunk fat mass	132	-4.7
Umami taste perception in obesity with metabolic syndrome	4	-3.7
Urinary potassium excretion	118	-13.8
Urinary sodium excretion	478	-5.0
Urine pH measurement	14	-3.1
Walking difficulty in Charcot-Marie-Tooth disease 1A	3	-3.4